Lisi Liu
Xun Duan
Baozhao Ju1*- 1School of Basic Medical Sciences, Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning, China
- 2Shenyang Institute of Automation, Chinese Academy of Sciences, Shenyang, Liaoning, China
Non-alcoholic steatohepatitis (NASH), the inflammatory progression of non-alcoholic fatty liver disease (NAFLD), is a leading cause of hepatocellular carcinoma (HCC) amid rising obesity and metabolic syndrome. This review elucidates the immunometabolic interplay driving NASH-HCC pathogenesis. Immune cells, including Kupffer cells, monocyte-derived macrophages, and T-cell subsets, orchestrate chronic inflammation and fibrosis via cytokine cascades (TNF-α, IL-1β, TGF-β1) and polarization shifts. Metabolic dysregulation—including insulin resistance, lipid accumulation, and oxidative stress—exacerbates hepatocyte injury, disrupts the balance between apoptosis and compensatory proliferation, and promotes immune evasion through pathways such as β-catenin/TNFRSF19 signaling and hypoxia-inducible factor 1-alpha (HIF-1α). Gut-liver axis alterations further amplify inflammation. Therapeutic advances include immunotherapies (PD-1 inhibitors combined with anti-angiogenics), metabolic regulators (PPARα/FXR agonists, GLP-1RAs), and lifestyle interventions, though NASH-HCC shows reduced immunotherapy efficacy due to unique immunosuppressive microenvironments. Future directions emphasize novel immune targets (MDSCs, SLAMF1), metabolic reprogramming, and microbiota modulation for precision therapies. Integrating multimodal approaches holds promise for halting NASH-to-HCC progression and improving outcomes.
1 Introduction
Non-alcoholic steatohepatitis (NASH), the progressive inflammatory form of non-alcoholic fatty liver disease (NAFLD), is a major contributor to chronic liver pathology and a recognized cause of hepatocellular carcinoma (HCC) in developed countries (1–3). NAFLD encompasses a spectrum of hepatic disorders, ranging from benign steatosis to NASH, which is characterized by lobular inflammation, varying degrees of fibrosis, and hepatocellular ballooning (4, 5). The global rise in obesity, type 2 diabetes mellitus (T2DM), and metabolic syndrome, which are significant risk factors for hepatic lipotoxicity and immunological dysfunction, parallels the increasing incidence of NASH-related HCC (6–8).
Epidemiological data show that over 25% of adults worldwide have NAFLD, with NASH responsible for a large share of liver-related illness and death (1, 9). The incidence of NASH and its complications, including cirrhosis and HCC, has risen significantly in regions such as Greater China and Japan. In China, NASH prevalence is estimated at 2.4% to 6.1% (10, 11). The growing number of liver transplants for NASH-induced end-stage liver disease underscores the need for effective diagnostic and treatment strategies (12).
The combination of metabolic load, mitochondrial dysfunction, and immune-mediated inflammation drives the complex pathophysiology of NASH and its development to HCC (2, 13–17). Insulin resistance worsens steatosis and disrupts lipid homeostasis, whereas hepatocyte lipid accumulation causes oxidative stress, endoplasmic reticulum (ER) stress, and pro-inflammatory signaling (14, 15). By interacting with hepatic stellate cells (HSCs) and other non-parenchymal cells, hepatic macrophage activation, including indigenous Kupffer cells and invading monocyte-derived populations, initiates inflammatory cascades and promotes fibrogenesis (18–20). Recent research has also shown the role of other immune cell subsets, including CD8+CXCR6+ T cells, innate lymphoid cells, and neutrophils, in forming the immunopathological milieu that promotes the development of HCC (21–25). Clarifying the immunometabolic processes underlying NASH-associated hepatocarcinogenesis has become crucial in light of this. Developments in experimental models, non-invasive diagnostics, and therapeutics are converging to improve our understanding of how diseases progress and enable tailored therapies (26, 27). In addition to highlighting existing clinical translation issues, this review summarizes recent findings on the immunological and metabolic interplay in NASH-associated HCC and investigates new treatment approaches aimed at preventing the progression from steatohepatitis to malignancy.
2 The role of immune cells in NASH
2.1 Composition of intrahepatic immune cells
The intrahepatic immune landscape in NASH is composed of diverse immune populations, including Kupffer cells (KCs), monocyte-derived macrophages (MoMFs), T cells, natural killer (NK) cells, and invariant natural killer T (iNKT) cells, all of which orchestrate disease pathogenesis. Under physiological conditions, KCs maintain immunological tolerance; however, in NASH, they become activated in response to lipotoxic stress and damage-associated molecular patterns (DAMPs), thereby initiating a cascade of pro-inflammatory cytokine release and subsequent immune cell recruitment (28, 29). Concurrently, infiltrating MoMFs differentiate into pro-inflammatory macrophages that engage and activate hepatic stellate cells (HSCs), thereby driving fibrogenic remodeling of the liver. Hepatic damage is exacerbated by a pathological shift in T cell subsets, including dysfunctional regulatory T cells (Tregs) and increased Th1/Th17 cells. CD4+ T cell modulation by fatty acids promotes fibrogenesis, while Treg dysfunction drives inflammation and steatosis (30–33). MAIT cells, which are abundant in the liver, mediate both beneficial and harmful reactions when they are dysfunctionally activated in chronic liver disease (34). In NASH-HCC, MAIT cells exhibit considerable metabolic plasticity, with altered glycolytic flux and mitochondrial function influencing their cytokine secretion profiles (35, 36). Upon activation by bacterial-derived riboflavin metabolites via MR1, MAIT cells produce pro-inflammatory cytokines such as IL-17 and IFN-γ, contributing to hepatic inflammation and fibrosis (37, 38). Chronic lipid accumulation and oxidative stress in the NASH liver impair MAIT cell function, shifting them toward a dysfunctional phenotype that paradoxically exacerbates immune dysregulation rather than protecting the tissue (39, 40). Similarly, γδ T cells, which serve as a bridge between innate and adaptive immunity, are increasingly recognized for their role in NASH-driven hepatocarcinogenesis. These cells respond rapidly to non-peptide antigens and produce IL-17A in response to inflammatory cues and free fatty acid accumulation. IL-17–producing γδ T cells promote fibrogenesis by activating hepatic stellate cells and recruiting neutrophils, while also facilitating tumor-promoting inflammation through sustained NF-κB activation (41, 42). Their metabolic programming is tightly linked to fatty acid oxidation (FAO) and mTORC1 signaling, both of which are influenced by the nutrient-rich, lipotoxic hepatic environment (43, 44). Furthermore, group 1 and group 3 innate lymphoid cells (ILCs) infiltrate the NASH liver and are shaped by local metabolic signals, including hypoxia-induced HIF-1α and microbiota-derived short-chain fatty acids (SCFAs) (45, 46). Group 3 ILCs produce IL-22 and IL-17, contributing to epithelial regeneration and inflammation, whereas group 1 ILCs, akin to NK cells, exhibit reduced cytotoxicity under lipid stress. Importantly, IL-15 signaling and altered lipid metabolism regulate ILC survival and function, implicating these cells as metabolically sensitive immunomodulators in the NASH-HCC transition (47–51) (Figure 1).
Figure 1. Main NAFLD/NASH macrophage polarization and activation factors. Resident KCs or recruited monocytes produce liver macrophages. Monocytes may be polarized into standard or alternative M1- or M2-type macrophages in vitro. In NASH, M1 macrophages cause inflammation whereas M2 macrophages reduce it. M2 macrophages produce IL10, which activates arginase to specifically apoptosis M1 KCs with high iNOS levels. LPS, FFAs, leptin, and cholesterol and oxLDL may activate KCs, FFAs, LEPR from adipose tissue, and CD36 and SRA in NAFLD/NASH. KCs release TNF, IL-1β, and IL-6 to maintain neutrophil balance. In NAFLD, monocytes become M1 macrophages, worsening hepatic inflammation. Key terms: NAFLD, NASH, KCs, IL-10, iNOS, LPS, TLRs, FFAs, LEPR, oxLDL, SRA, TNF, IL-1β.
Although both tissue-resident and circulating natural killer (NK) cell subsets actively surveil activated hepatic stellate cells (HSCs) and stressed hepatocytes, their cytotoxic function is attenuated in NASH and negatively correlates with fibrosis severity (52, 53). Invariant natural killer T (iNKT) cells further modulate the inflammatory milieu via cytokine secretion and cell–cell interactions (54). During inflammation, liver sinusoidal endothelial cells (LSECs) act as gatekeepers, promoting immune cell adherence and retention (55). Additionally, the gut-liver axis integrates systemic metabolic signals with local immunity by influencing immunological composition and activation via metabolites produced from the microbiota (56, 57). Microbial-derived metabolites, particularly short-chain fatty acids (SCFAs) and secondary bile acids, can modulate Kupffer cell polarization and T cell differentiation (58–60). SCFAs such as butyrate and propionate, through G-protein coupled receptors (GPR41, GPR43), enhance Treg development and suppress pro-inflammatory Th17 responses, thereby maintaining immune tolerance (61). Conversely, dysbiosis-associated shifts in bile acid composition can impair FXR–TGR5 signaling, promoting Kupffer cell M1 polarization and pro-inflammatory cytokine production (62). Certain pathobionts such as Escherichia coli and Bacteroides species have been linked to increased endotoxemia and LPS translocation, which further activates TLR4–NF-κB pathways in hepatic macrophages, aggravating inflammation and fibrosis (63, 64). Importantly, microbial imbalance has been implicated in resistance to immune checkpoint inhibitors (ICIs) by reshaping the tumor immune microenvironment, such as reducing CD8+ T cell infiltration or inducing myeloid-derived suppressor cells (MDSCs) (65–67). Thus, targeting the gut microbiota and its metabolites represents a promising avenue to reprogram intrahepatic immunity and enhance therapeutic responses in NASH-HCC. Single-cell transcriptomic analyses have uncovered profound immune heterogeneity in NAFLD/NASH, identifying distinct T cell and macrophage subsets with context-dependent immunoregulatory or pathogenic roles (68, 69). The interplay between pro-inflammatory and regulatory immune populations orchestrates hepatic inflammation and fibrogenesis, collectively offering a framework for the development of immunomodulatory therapeutic strategies in NASH.
2.2 Immune cell activation and inflammatory response
Chronic hepatic inflammation is a principal driver of disease progression from NAFLD to NASH, fibrosis, and ultimately HCC. Hepatocyte injury, metabolic stress, and lipotoxicity collectively activate immune cells within the hepatic microenvironment, initiating a cytokine-driven inflammatory cascade (70). Resident Kupffer cells and monocyte-derived macrophages (MoDMacs) recognize gut-derived pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) via pattern recognition receptors (PRRs), including Toll-like receptors (TLRs) and NOD-like receptors (NLRs), leading to activation of NF-κB and inflammasome signaling pathways. This results in the secretion of key pro-inflammatory and profibrotic cytokines such as TNF-α, IL-1β, and TGF-β1 (18, 71–73). Macrophage polarization plays a key role in disease development: M1-like macrophages worsen tissue damage, while M2-like macrophages promote fibrogenesis via TGF-β1 despite their role in tissue healing. This phenotypic equilibrium in KCs is controlled by galectin-12 (71). By producing cytokines that attract immune cells and stimulate hepatic stellate cells (HSCs), neutrophils, NK cells, and ILCs, these cells increase inflammation (74, 75). Adaptive immune responses further aggravate pathology: CD4+ and CD8+ T cells, including dysfunctional regulatory T cells and T-bet–driven pro-inflammatory subsets, potentiate hepatocellular injury and IFN-γ production (76, 77). Complement-derived C3a and C5a encourage immunological recruitment, but ROS and DAMPs from lipotoxic hepatocytes activate NLRP3 inflammasomes (78–80). By triggering hepatic PRRs and inducing cytokine production, gut-derived endotoxins, such as LPS, worsen liver inflammation (81, 82). The ensuing cytokine milieu (TNF-α, IL-1β, IL-6, and TGF-β1) reinforces a self-reinforcing cycle of inflammation and fibrosis by sustaining immunological activation and initiating HSC-mediated fibrogenesis (18, 83). Notably, the NLRP3 inflammasome serves as a central molecular bridge linking metabolic stress to immune activation. Lipotoxic hepatocytes release ROS and DAMPs, which activate NLRP3 through mitochondrial dysfunction, potassium efflux, and endoplasmic reticulum (ER) stress (84, 85). Upon activation, NLRP3 promotes the cleavage of pro-caspase-1 into active caspase-1, leading to the maturation of IL-1β and IL-18, key amplifiers of hepatic inflammation (86–88). This cascade augments macrophage and neutrophil recruitment and perpetuates hepatocyte damage, fibrosis, and immune cell dysregulation. The intersection of ROS accumulation, lipid peroxidation, and TLR signaling further potentiates NLRP3 activity, situating it at the nexus of metabolic and immunologic injury in NASH (89, 90). Therapeutic targeting of NLRP3—via GPR81 agonists, AMPK activators, or miRNA regulators (miR-137-3p)—has shown promise in attenuating this harmful axis in preclinical studies (88, 91). Targeting immune signaling pathways has become a central focus in emerging therapeutic strategies. Inhibitors of chemokine receptors block immune cell infiltration, while peroxisome proliferator-activated receptor (PPAR) agonists modulate macrophage polarization to shift immune balance. Additionally, phytochemicals such as paeoniflorin and magnoflorine have demonstrated efficacy in dampening inflammatory cascades (92–95) (Figure 2).
Figure 2. Immune-metabolic dysregulation in NAFLD/NASH-HCC progression and therapeutic strategies. This schematic summarizes how immune and metabolic dysfunction drive immune escape and tumor promotion in NASH-related HCC. On the left, metabolic stress in the NAFLD/NASH microenvironment causes the death of cytotoxic CD4+ T cells and expansion of auto-aggressive CXCR6+ CD8+ T cells, fostering hepatocarcinogenesis. On the right, β-catenin (CTNNB1) mutations activate the TNFRSF19 pathway, suppressing pro-inflammatory cytokines (IL-6, CXCL8) and impairing immune cell recruitment, thereby inducing immune exclusion. Together, these processes coupled with chronic metabolic dysregulation—create an immunosuppressive microenvironment that promotes HCC progression.
2.3 Polarization and metabolic regulation of immune cells
The polarization of immune cells, especially macrophages, significantly impacts metabolic balance in disease states such as NAFLD and HCC. Glycolysis and oxidative phosphorylation (OXPHOS) are the hallmarks of the pro-inflammatory M1 and anti-inflammatory M2 states that macrophages may adopt due to their metabolic flexibility. While M2 macrophages encourage tissue remodeling via fatty acid oxidation (FAO) and immunosuppression, M1 macrophages increase metabolic inflammation by glycolytic reprogramming and cytokine production (96, 97). In addition to serving as a metabolic substrate, tumor-derived lactate also functions as a signaling molecule that promotes immune evasion by polarizing tumor-associated macrophages (TAMs) toward an M2-like phenotype (98, 99). To fine-tune macrophage fate, molecular regulators such as Sirtuins and lncRNAs integrate metabolic signals with epigenetic regulation (100, 101). Tryptophan metabolism and serine metabolism via IGF1-p38 signaling are two metabolic pathways that directly alter M1/M2 balance, influence inflammatory tone, and influence treatment responses (102, 103). The polarization axis affects fibrotic and inflammatory cascades in hepatic diseases: M1 macrophages worsen damage, while M2 macrophages promote fibrogenesis by releasing TGF-β1 and other mediators. Hepatocyte PPAR-γ–ROS signaling and galectin-12 both influence Kupffer cell fate (71, 104). In addition to macrophages, metabolic reprogramming occurs in neutrophils and dendritic cells, suggesting broader immunometabolic vulnerabilities that may be exploited in cancer and chronic inflammation (105).
3 The impact of metabolic disorders on NASH
3.1 Insulin resistance
One of the main pathogenic mechanisms in NAFLD and its progressive form, NASH, is insulin resistance (IR). IR disturbs glucose and lipid homeostasis and is characterized by compromised insulin signaling in the liver, adipose tissue, and skeletal muscle. By boosting adipose lipolysis, increasing free fatty acid influx, and promoting de novo lipogenesis, IR increases hepatic steatosis in NAFLD, while ironically failing to reduce gluconeogenesis (106, 107). Selective insulin resistance in the liver leads to compensatory hyperinsulinemia and metabolic dysregulation, further disrupting systemic energy balance. The early pathogenic significance of NAFLD is shown by pediatric findings that link its increased incidence with IR and metabolic syndrome (107). Mechanistically, inflammation, oxidative stress, and mitochondrial dysfunction exacerbate IR, which is caused by poor PI3K-Akt signaling and faulty insulin receptor substrate (IRS-1/2) phosphorylation (72, 108). Through mTORC1-SREBP1c activation and compromised insulin signaling, disruption of the hedgehog pathway, especially hepatocyte Smo deletion, causes steatosis and systemic IR (109). Through immunological activation and the involvement of the inflammasome, IR also promotes hepatic inflammation. Notably, activation of the NLRP3 inflammasome increases liver damage by generating IL-1β and IL-18 and disrupts insulin signaling by causing serine phosphorylation of IRS-1. These effects are lessened by GPR81 agonism, making it a potentially useful therapeutic target (110). Even in those who are not obese, IR clinically correlates with NAFLD severity, as indicated by HOMA-IR, TyG, and LP-IR, and shows phenotypic variability (111–113). Genetically driven NAFLD and IR do not seem to be causally related, according to Mendelian randomization experiments, suggesting that the processes are either shared or subtype-specific (114). Through oxidative and lipogenic mechanisms, dietary variables, especially excessive fructose and artificial sweeteners, exacerbate IR and steatosis (115, 116). Insulin-sensitizing drugs (GLP-1R, PPAR, and FXR agonists), lifestyle changes, and new regulators like AMPK, FGL1, and CaSR are examples of therapeutic approaches (117–121). IR is a key target in the treatment of NAFLD and NASH because it coordinates hepatic lipid excess, inflammation, and systemic metabolic imbalance.
3.2 Lipid metabolism abnormalities
Lipid metabolic abnormalities play a key role in the development of NAFLD, which leads to NASH, fibrosis, and HCC. Excessive triglyceride and cholesterol buildup is a sign of dysregulated hepatic lipid homeostasis, which impairs hepatocyte function and causes lipotoxicity. Environmental pollutants such as pyrethroids and exposure to high-fat diets (HFDs) have been shown to block β-oxidation regulators (CPT-1) and upregulate lipogenic genes (SREBPs, FAS, and ACC), thereby increasing lipid accumulation and hepatocellular damage (122, 123). ACLY, a crucial link between glycolysis and lipogenesis, drives NASH-HCC progression. In a high-fat/fructose western diet and diethyl nitrosamine injection (WD-DEN) model, ACLY knockout decreased lesion burden, tumor lipid content, and SREBF1 expression by approximately 70%. It also reversed immunosuppression by restoring CD8+ T cell IFN-γ secretion and reducing lactate (124). AMPK, a metabolic sensor that, when activated, inhibits lipogenesis and encourages fatty acid oxidation, is essential to these processes (123, 125). Through the LKB1/AMPK axis, substances such as coniferaldehyde help improve lipid and glucose dysregulation (125). AMPK interacts with the NAD+-dependent deacetylase SIRT1, forming the AMPK–SIRT1 axis, which promotes mitochondrial biogenesis, autophagy, and anti-inflammatory responses by deacetylating transcriptional regulators such as PGC-1α and NF-κB (126, 127). This signaling network not only facilitates metabolic homeostasis but also alleviates immune exhaustion by enhancing regulatory T cell survival and repressing macrophage M1 polarization (128). Meanwhile, activation of PPARα—a nuclear receptor transcription factor—is tightly coupled to fatty acid oxidation (FAO) and modulates the immune landscape by promoting M2 macrophage polarization, reducing proinflammatory cytokine secretion (TNF-α, IL-6), and restoring immune tolerance (129, 130). Dysfunction of these immunometabolic circuits fosters chronic inflammation and immune evasion in NASH-HCC (131, 132). Together, the AMPK–SIRT1 and PPARα–FAO axes serve as central hubs connecting metabolic stress with immune dysregulation in steatohepatitic carcinogenesis, providing promising therapeutic targets.
Conversely, aberrant activation of liver X receptors (LXR) and suppression of peroxisome proliferator-activated receptor α (PPARα) exacerbate hepatic steatosis and inflammation by disrupting lipid trafficking and immune crosstalk (123, 133). Mitochondrial dysfunction further amplifies lipid imbalance by impairing β-oxidation and promoting reactive oxygen species accumulation and apoptosis (134). In parallel, lysosomal impairment compromises lipid catabolism, thereby aggravating the progression of NAFLD (135). F OXK1, a downstream effector of mTORC1, has also been implicated in promoting steatosis through suppression of fatty acid oxidation (136). Lipid overload mechanistically bridges metabolic stress to immune dysregulation by activating complement cascades, Toll-like receptor (TLR) signaling, and driving macrophage polarization (80, 137). TREM2+ macrophages signify an immunometabolic adaptation that attenuates oxidative injury in NAFLD (138). Hepatocellular lipid management and inflammation are regulated by extracellular vesicles (139), and metabolic and inflammatory pathways are further adjusted by genetic variations (APOH) and epigenetic modulators (miRNAs) (140–143). Emerging treatments with translational potential include those that target AMPK, PPARα, or SREBPs (144), as well as natural substances such as resveratrol, sesamin, anthocyanins, and fucoxanthin (145–148). Additionally, interventions targeting autophagy, endoplasmic reticulum stress, and mitochondrial integrity show promise in preclinical models (135, 149).
3.3 Inflammation and oxidative stress
Metabolic dysregulation in non-alcoholic fatty liver disease (NAFLD) initiates a self-perpetuating cycle of oxidative stress and inflammation, accelerating fibrosis and hepatocellular damage. Lipid overload—particularly from free fatty acids (FFAs)—exceeds the liver’s antioxidant defenses, leading to lipotoxicity and mitochondrial dysfunction (150, 151). Impaired electron transport chain (ETC) activity further intensifies lipid peroxidation and oxidative injury while triggering pro-inflammatory signaling cascades, notably NF-κB activation. This promotes the upregulation of TNF-α, IL-6, and IL-1β, thereby recruiting hepatic immune populations such as Kupffer cells and infiltrating macrophages (152–154). Inflammation and ROS accumulation are reinforced by insulin resistance associated with metabolic syndrome, which also promotes de novo lipogenesis and suppresses fatty acid oxidation (155). Although blockade of the endocannabinoid system exhibits anti-inflammatory potential, CB1 receptor activation paradoxically exacerbates oxidative and nitrosative stress (153).
Multiple regulatory pathways modulate this pathogenic feedback. For example, interventions like Gegen Qinlian Decoction and fucoxanthin attenuate oxidative damage through activation of the AMPK/Nrf2 axis, a key modulator of cellular antioxidant responses (156, 157). MicroRNAs such as miR-137-3p and miR-665-3p further regulate oxidative and inflammatory cascades at the post-transcriptional level (158, 159). In NAFLD, endothelial dysfunction is made worse by chronic intermittent hypoxia, which is frequent in obstructive sleep apnea and exacerbates oxidative damage (160). The transition from basic steatosis to NASH and HCC is facilitated by this reciprocal amplification between ROS and inflammation (161, 162). Therapeutic strategies targeting this axis—such as omarigliptin, probiotics, nobiletin, and resveratrol—have demonstrated efficacy in mitigating hepatic oxidative and inflammatory damage (163, 164).
4 The mechanisms linking NASH and hepatocellular carcinoma
4.1 Apoptosis and hepatocyte proliferation
Disruption of the delicate balance between hepatocyte death and compensatory proliferation constitutes a critical driver of hepatocarcinogenesis. In diet-induced obesity (DIO) mouse models, a high-fat diet (HFD) induces hepatic steatosis accompanied by elevated oxidative stress, dysregulated insulin and glucose signaling, and aberrant lipid metabolism. These metabolic insults synergistically promote hepatocyte apoptosis, as evidenced by increased caspase-3 activity and upregulation of apoptosis-related genes. Concurrently, hepatocyte proliferation is diminished, indicating a breakdown in the homeostatic coupling of cell death and regeneration (165). This imbalance not only accelerates cellular turnover but also heightens the risk of replication-induced mutagenesis, facilitating the accumulation of somatic mutations. Sustained oxidative stress—central to NASH pathology—further compounds genomic instability through ROS-mediated DNA lesions such as 8-oxoguanine (166, 167). Inflammatory conditions impair DNA repair mechanisms, intensifying mutation load and fostering a pro-tumorigenic environment through the uncoupling of apoptosis and regenerative proliferation (168).
Studies employing genetically engineered mice lacking the pro-survival BCL-2 family protein myeloid cell leukemia 1 have yielded mechanistic insights into hepatocarcinogenesis in NASH. In hepatocyte-specific Mcl1-deficient mice subjected to a NASH-inducing diet, marked increases in hepatocyte death, inflammation, fibrosis, and compensatory proliferation were observed. Notably, these mice developed liver tumors with histological hallmarks of hepatocellular carcinoma (HCC) at significantly higher frequencies than controls, underscoring the paradox whereby excessive hepatocyte apoptosis may drive carcinogenesis in NASH (169). In NASH, the hepatic integrated stress response (ISR) controls hepatocyte fate at the molecular level by inhibiting the somatotroph axis via ATF3, which lowers inflammation and apoptosis while simultaneously reducing hepatocyte proliferation (170). Despite reducing cell death, this suppression worsens fibrosis, underscoring the intricate relationship between apoptosis and proliferation during the course of illness. Moreover, ISR dysregulation under metabolic stress has been implicated in impaired DNA repair and the clonal expansion of mutated hepatocytes, providing an additional pathway to mutagenesis and HCC development (171). Intriguingly, replenishment of NAD+ has been shown to restore proliferative capacity and ameliorate liver injury, potentially counteracting ISR-mediated hepatocarcinogenic processes (170).
Several signaling pathways and variables influence this equilibrium. For example, substances such as Ginsenoside Rb1 may reduce HFD-induced hepatocyte apoptosis by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), indicating therapeutic potential for modifying apoptotic pathways (172). On the other hand, environmental pollutants that block the AMPK and PPAR-γ pathways worsen hepatocyte death and steatohepatitis, suggesting that these pathways have protective functions (173). The importance of proliferation in liver repair and carcinogenesis is further highlighted by the fact that proliferating cell nuclear antigen (PCNA), a marker of DNA synthesis and cell proliferation, is downregulated in steatotic livers but can be targeted by agents such as avachinin to promote hepatocyte regeneration and reduce apoptosis (174). Oxidative stress, a hallmark of non-alcoholic steatohepatitis (NASH), also impairs proliferative responses and promotes apoptosis. NADPH oxidases (NOX enzymes) serve as key effectors linking metabolic dysfunction to cell injury by generating reactive oxygen species (ROS) that drive hepatocyte damage (175). Therapeutic antioxidant strategies, including molecular hydrogen administration, have been shown to mitigate steatosis and fibrosis by dampening inflammation and apoptotic signaling (176).
4.2 Immune evasion mechanisms
Hepatocellular carcinoma, particularly in the context of NAFLD and its progressive form NASH, employs diverse strategies to evade immune surveillance. These mechanisms can be broadly categorized into three distinct yet interrelated pathways. Oncogenic activation of β-catenin (CTNNB1), frequently observed in NAFLD-related HCC, drives immune exclusion by disrupting immune cell recruitment. Specifically, CTNNB1 mutations upregulate TNFRSF19, a receptor that suppresses senescence-associated cytokines such as IL-6 and CXCL8, thereby impairing pro-inflammatory signaling required for effective immune infiltration. This immune-silent tumor phenotype can be partially reversed by Wnt inhibitors, underscoring the β-catenin/TNFRSF19 axis as a pivotal mediator of immune evasion and a promising therapeutic target (177) (Figure 3). Distinct metabolic features of NASH contribute to T cell dysfunction. Lipid accumulation and altered fatty acid metabolism result in apoptosis of cytotoxic CD4+ T cells and expansion of auto-aggressive CXCR6+ CD8+ T cells, which paradoxically promote tumor growth. These CD8+PD-1+CXCR6+ subsets display transcriptional and functional exhaustion profiles, contributing to a suppressive tumor microenvironment. Notably, their persistence despite ICIs therapy has been associated with poor treatment responsiveness, suggesting their role as potential resistance factors. Moreover, their unique phenotypic features and enrichment in NASH-associated HCC highlight their utility as prognostic biomarkers and immunotherapeutic targets under active investigation. These dysfunctional CD8+ T cells are enriched in steatohepatitic HCC (SH-HCC), which also displays CPT2 downregulation and oncometabolite accumulation, further exacerbating immune evasion. These metabolic shifts reflect a reprogrammed tumor microenvironment that suppresses effective antitumor immunity (178). Cytokine-driven immune suppression. Certain cytokines, particularly IL-22, contribute to immune evasion by modulating the tumor microenvironment. Produced by T cells and innate lymphoid cells, IL-22 has dual roles—while protective in early liver injury, it also promotes tumor cell proliferation, survival, and immune suppression in advanced disease states. Elevated IL-22 signaling in HCC has been linked to poor prognosis and reduced efficacy of immunotherapies (179). Moreover, NAFLD-HCC exhibits an altered immune landscape with lower responsiveness to ICIs, partly due to these cytokine-mediated suppressive mechanisms (180, 181) (Table 1).
Figure 3. Mechanisms of immune evasion in NAFLD/NASH-associated hepatocellular carcinoma. Liver tumors in NAFLD/NASH evade immunity through β-catenin (CTNNB1)–TNFRSF19–mediated cytokine suppression (IL-6, CXCL8), metabolic stress–induced CD4+ T-cell loss, expansion of CXCR6+ CD8+ T cells, and IL-22–driven tumor survival. These pathways collectively create an immunosuppressive microenvironment, reducing the effectiveness of immune checkpoint inhibitors and promoting HCC progression.
Table 1. Integrated immunometabolic mechanisms driving NASH-associated hepatocellular carcinoma (HCC).
4.3 Changes in the microenvironment
The microenvironment of NASH, a progressive type of NAFLD, significantly influences the pathophysiology and development of HCC. Chronic inflammation, hepatocyte damage, fibrosis, and metabolic dysregulation are the hallmarks of NASH, and they all work together to create an environment that is conducive to tumor growth. The prolonged inflammatory state caused by immune cell infiltration and activation is a key characteristic of the NASH microenvironment. Macrophages, especially those surrounding dead hepatocytes in crown-like formations, exhibit unique gene expression patterns that support tumor growth and fibrosis induced by metabolic stress (182). Together with activated fibroblasts that drive cancer-related pathways, these NASH-specific macrophages create a favorable environment for hepatocarcinogenesis. The presence of immunosuppressive cell subsets, such as regulatory T cells (Tregs), which impede efficient antitumor immune responses and facilitate tumor immune evasion, further complicates the immunological landscape in NASH-related HCC (183). Furthermore, it has been shown that metabolic changes in the NASH milieu, such as dysregulated lipid metabolism and cholesterol accumulation, affect the activity of natural killer T (NKT) cells, compromising antitumor immunosurveillance and promoting tumor growth (184). Hepatocyte-derived hypoxia-inducible factor 1-alpha (HIF1A) activation during NASH progression results in metabolic reprogramming, angiogenesis, and immunosuppressive macrophage polarization, all of which promote tumorigenesis (185). Hypoxia itself emerges as a pivotal determinant of the NASH tumor microenvironment. Moreover, interactions between microenvironmental factors and genetic alterations—such as CTNNB1 mutations frequently observed in NAFLD-HCC—contribute to immune evasion by suppressing senescence-associated secretory phenotypes and promoting immune exclusion (177). Perturbations in gut microbiota composition and metabolite production also modulate hepatic immunity, fibrosis, and inflammation, thereby expediting the transition from metabolic-dysfunction-associated steatotic liver disease to HCC (186, 187). Extracellular matrix (ECM) remodeling, a hallmark of NASH fibrosis, further reinforces tumor progression by offering structural support for invasion and metastasis (188). Notably, the immunosuppressive microenvironment may underlie the suboptimal efficacy of immune checkpoint blockade in NAFLD-HCC; however, combinatorial regimens incorporating anti-angiogenic or metabolic modulators may enhance clinical outcomes (189, 190) (Figure 4).
Figure 4. Immune cells and metabolic dysregulation in NASH-associated hepatocellular carcinoma. Chronic lipid overload induces lipotoxicity, excessive reactive oxygen species (ROS) generation, oxidative stress, and activation of the NLRP3 inflammasome, promoting hepatic inflammation and steatosis. Concurrent insulin resistance exacerbates endoplasmic reticulum (ER) stress and mitochondrial dysfunction, further amplifying inflammatory signaling. These metabolic disturbances activate resident Kupffer cells and recruit monocyte-derived macrophages, reshaping the hepatic immune microenvironment and altering T cell and natural killer (NK) cell functions. Dysregulated cytokine signaling, including increased IFN-γ, IL-1, and TGF-β, together with aberrant β-catenin signaling, drives hepatocyte malignant transformation and HCC development. In parallel, gut–liver axis disruption leads to altered bile acid composition, impaired intestinal barrier integrity, and translocation of microbiota-derived metabolites, which modulate bile acid signaling and adaptive immune responses in the liver. This integrated metabolic–immunological network culminates in immune dysfunction and tumor progression. Potential therapeutic strategies targeting these pathways include metabolic modulators (GLP-1 receptor agonists, FXR agonists, PPAR agonists, and AMPK activators), immunotherapies such as immune checkpoint inhibitors and anti-inflammatory agents, and combination therapies that concurrently modulate metabolism, gut microbiota, and antitumor immunity.
5 Advances in therapeutic strategies
5.1 Emerging roles of immunotherapy in NASH-associated HCC
The accumulation of dysfunctional CD8+PD-1+ T cells in NASH paradoxically exacerbates liver injury upon PD-1 blockade, complicating immunotherapeutic outcomes in this context (191). Nevertheless, recent clinical data reveal that patients with NAFLD-associated HCC derive enhanced objective response rates and progression-free survival from combination regimens pairing immune checkpoint inhibitors (ICIs) with anti-angiogenic agents, notably the atezolizumab–bevacizumab protocol (189, 192). Furthermore, it has been suggested that altering metabolic pathways and the gut microbiome might improve the effectiveness of immunotherapy. The gut–liver axis plays a pivotal role in sculpting hepatic immune dynamics, and dysbiosis characteristic of NAFLD/NASH has been shown to modulate tumor progression and immune responses. Therapeutic modulation of microbial composition or host metabolism may recondition the tumor microenvironment, thereby enhancing ICI responsiveness (193, 194). Recent studies also emphasize the contribution of new immune cell subsets to the immunological landscape in chronic liver disease and HCC, including tissue-resident memory T cells and γδT cells. To minimize liver damage and reestablish efficient antitumor immunity, these cells might be targeted for precision immunotherapy (195, 196). The immune-related transcriptional signatures—such as estrogen pathway–associated gene panels—have been developed to stratify patients by predicted immunotherapy responsiveness, thus enabling more personalized treatment strategies (197). Despite these advancements, optimizing immunotherapy for NASH-related HCC remains challenging. Heterogeneity in immune dysfunction, metabolic rewiring, and susceptibility to immune-mediated hepatic damage necessitates careful patient selection and tailored combinatorial approaches. Ongoing clinical trials are actively evaluating ICI efficacy in diverse HCC subpopulations, including those with underlying metabolic liver disease, and are testing regimens incorporating anti-angiogenic agents, metabolic modulators, and microbiome-based interventions (198–200). Furthermore, the metabolic reprogramming and chronic inflammation characteristic of NASH-HCC contribute to T cell exhaustion and impaired persistence of adoptively transferred cells (201, 202). The fibrotic stroma, elevated levels of inhibitory cytokines (IL-10, TGF-β), and lipid accumulation within the TME further hinder the expansion, trafficking, and cytotoxic function of engineered T cells (203, 204). These microenvironmental constraints underscore the need to optimize CAR-T/TCR strategies for liver cancer by incorporating metabolic modulators, improving antigen specificity, and targeting immunosuppressive cues unique to NASH-related HCC.
5.2 Metabolic regulatory drugs
With the development of new metabolic regulatory medications targeting key pathways in lipid metabolism, inflammation, and fibrosis, the therapy landscape for NASH, a progressive variant of NAFLD, is undergoing significant transformation. These medications seek to address the underlying metabolic abnormalities that cause hepatic damage and steatosis. Among them, agonists of the peroxisome proliferator-activated receptor alpha (PPARα) have attracted significant interest due to their critical role in regulating lipid oxidation and reducing hepatic inflammation. To promote lipid oxidation and mitigate steatosis, recent research has proposed new selective PPARα modulators, such as the DY series, which have shown effectiveness in upregulating PPARα target genes implicated in NASH pathogenesis (205). In addition, it has been demonstrated that a crucial mechanism for promoting fatty acid β-oxidation is the SIRT1/PGC-1α/PPARα signaling axis. In NASH models, a natural substance called formononetin improves hepatic steatosis and lipid metabolism by activating this system (206). Activation of the farnesoid X receptor (FXR)—a bile acid–sensing nuclear receptor that governs bile acid, lipid, and glucose metabolism—exerts suppressive effects on hepatic steatosis and fibrosis. Obeticholic acid (OCA), the first FXR agonist to reach clinical trials for NASH, demonstrated modest hepatoprotective efficacy; however, its clinical utility has been constrained by adverse events such as pruritus and dyslipidemia (207). Despite these challenges, ongoing efforts are focused on refining FXR-targeted therapies through the development of more selective agonists and combinatorial strategies to enhance efficacy while mitigating toxicity (207, 208). Notably, the gut microbiota–FXR axis has emerged as a compelling therapeutic avenue, as microbial modulation of bile acid composition profoundly influences FXR signaling, thereby shaping systemic metabolism and the trajectory of NAFLD progression (209).
The endocrine roles of fibroblast growth factors (FGFs), particularly FGF19 and FGF21, in regulating lipid and glucose metabolism have recently garnered attention. Clinical trials of FGF-based therapies have demonstrated promising efficacy in alleviating steatosis, inflammation, and fibrosis in patients with NAFLD (210). Enhancing insulin sensitivity and increasing energy expenditure are two of these medicines’ pleiotropic effects, which are essential for metabolic correction in NASH. Hepatocyte-expressed G protein-coupled receptors (GPCRs) are also desirable targets for drugs because of their regulatory functions in liver metabolism. The liver is thought to harbor more than 50 GPCRs, and altering these receptors might affect lipid and glucose balance, opening new treatment options for NASH (211). Additionally, targeting cholesterol transporters such as NPC1L1, implicated in cholesterol absorption and NASH progression, has been proposed to rebalance cholesterol metabolism (212). Activation of AMPK, a master regulator of cellular energy status, offers dual benefits by promoting lipid catabolism and reducing oxidative stress. Gossypetin, a naturally derived flavonoid, attenuates hepatic steatosis, inflammation, and fibrosis in NASH models through both antioxidant activity and AMPK activation (213). Similarly, GLP-1RAs ameliorate hepatic lipid accumulation by modulating lipid turnover and inducing autophagy via the AMPK/SIRT1 axis (214). Preclinical research suggests that peripheral serotonin receptor antagonists targeting 5-HT2A receptors may decrease hepatic fat accumulation without adverse effects on the central nervous system (215). Natural compounds such as brown algae–derived plant polysaccharides have shown hepatoprotective properties, including modulation of gut microbiota, suppression of hepatic inflammation, and regulation of lipid metabolism, offering low-toxicity adjunctive options for NASH intervention (216–218).
Recent findings indicate that exosomes derived from mesenchymal stem cells (MSCs) can ameliorate hepatic steatosis by enhancing fatty acid oxidation and suppressing lipogenesis through CAMKK1-mediated activation of AMPK, offering a novel biologic strategy for NASH treatment (219). Despite such promising advances, the development of safe and effective metabolic therapies for NASH remains challenged by the disease’s complex pathophysiology, characterized by intertwined fibrotic, inflammatory, and metabolic signaling networks. To address this complexity, combinatorial therapeutic strategies—targeting multiple pathogenic axes either concurrently or in sequence—are increasingly being explored to maximize efficacy while minimizing adverse effects (220). Furthermore, leveraging precision medicine approaches, including patient-specific genomic, epigenomic, and microbiome profiling, holds substantial promise for tailoring metabolic therapies to individual disease phenotypes, thereby enhancing therapeutic responsiveness and long-term outcomes (221, 222).
5.3 Nutritional interventions and lifestyle modifications
In the continued absence of approved pharmacological therapies, lifestyle interventions remain the primary strategy for managing NAFLD and its progressive form, NASH. Robust evidence indicates that weight loss achieved through dietary modification and enhanced physical activity ameliorates hepatic steatosis, inflammation, and even fibrosis, thereby reducing the progression to cirrhosis and HCC (223, 224). Given the frequent coexistence of cardiometabolic disorders in NAFLD, dietary interventions such as the Mediterranean diet—rich in monounsaturated fats, fiber, and antioxidants—have demonstrated beneficial metabolic effects independent of caloric restriction, improving both liver fat accumulation and cardiovascular risk profiles (225, 226). Alternative dietary strategies, including intermittent fasting, the Dietary Approaches to Stop Hypertension (DASH) diet, and ketogenic regimens, have also yielded encouraging results in improving hepatic histology and metabolic homeostasis (225). Physical activity, encompassing both aerobic and resistance training, enhances insulin sensitivity and contributes to weight reduction, both critical factors in NAFLD pathogenesis. Importantly, these lifestyle modifications not only reduce hepatic lipid burden but also mitigate the risk of type 2 diabetes and cardiovascular disease—the principal causes of mortality in patients with NAFLD (227, 228).
Genetic variables, such as the PNPLA3 rs738409 polymorphism, which alters responsiveness to diet and exercise regimens, might affect the success of lifestyle interventions, underscoring the need for individualized methods (229). In pediatric populations, early lifestyle interventions focusing on low-fat, low-sugar diets and increased physical activity are critical for halting NASH progression and improving both metabolic and psychosocial outcomes (230, 231). However, long-term adherence to lifestyle modifications remains challenging, with fewer than half of patients achieving sustained weight loss sufficient to improve hepatic histology (232). With promising results in weight reduction and metabolic improvements, emerging endoscopic bariatric procedures offer less-invasive alternatives to surgery and may help alleviate NAFLD/NASH (232, 233). Specific bioactive dietary components, including branched fatty acid esters of hydroxyl fatty acids (9-PAHSA), have shown hepatoprotective and anti-inflammatory effects in animal models, suggesting possible adjuvant functions for nutritional supplements beyond weight reduction (223). The complex benefits of diet and exercise are further supported by the fact that lifestyle changes affect intestinal barrier integrity and gut microbiota composition, which are increasingly recognized as essential modulators of NAFLD development and hepatocarcinogenesis (187). Lifestyle interventions contribute to improved health-related quality of life, particularly in domains related to physical functioning (226, 234, 235).
6 Future research directions
6.1 New immune targets
Given the intricate interactions between immune dysregulation and metabolic abnormalities that propel disease progression and the development of HCC, the investigation of novel immune targets in the setting of NASH is essential for developing treatment approaches. The liver’s distinct immune milieu, which includes a wide range of innate and adaptive immune cells such as T cells, natural killer (NK) cells, macrophages, dendritic cells, and liver-resident cells, including Kupffer cells and hepatic stellate cells, has been highlighted in recent research. In NASH and associated liver malignancies, these cells support the immunosuppressive microenvironment that promotes carcinogenesis, fibrosis, and chronic inflammation (236). Targeting immunological checkpoints and signaling pathways that regulate immune cell activation and fatigue is one potential approach. For example, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and the PD-1/PD-L1 axis have been linked to the compromised anti-tumor immune responses seen in NASH-associated HCC, even though clinical responses to ICIs in this context are still inconsistent and occasionally suboptimal (190, 237). This variation underscores the need to identify new immune modulators and combinatorial approaches tailored to the inflammatory and metabolic environment of NASH. MDSCs, which proliferate in chronic liver disease and have potent immunosuppressive effects, are implicated in the development of immunotherapy resistance and disease progression, according to new research. An innovative immunotherapeutic approach to effectively restore anti-tumor immunity in NASH-HCC is to target MDSCs and the signaling pathways that are linked to them (238).
Recent studies have identified novel immune receptors, such as signaling lymphocytic activation molecule family 1 (SLAMF1), as key mediators of hepatocyte death, positioning them as potential biomarkers for NASH and therapeutic targets to mitigate immune-driven hepatic injury (239). Targeting immunometabolism may improve therapeutic efficacy because immune cell function and phenotype are also influenced by metabolic reprogramming in the NASH liver microenvironment, characterized by altered glycolysis, oxidative phosphorylation, and lipid metabolism (240).
Extracellular vesicles (EVs) and toll-like receptor 4 (TLR4) signaling are important in regulating inflammation and immune responses in NASH and HCC (241). The gut–liver axis, along with microbiota-derived metabolites, has been shown to modulate intrahepatic immune responses, suggesting that microbiota-targeted therapies may indirectly reprogram immune dynamics in NASH (242). Kinase inhibitors may act as supplemental immune modulators, and protein kinases implicated in metabolic and inflammatory signaling pathways are being recognized as critical molecular contributions to the development of HCC and NASH pathophysiology (243). Preclinical models of NASH-HCC have demonstrated that agents such as 6-gingerol can potentiate anti-tumor immunity by reprogramming tumor-associated macrophages toward a pro-inflammatory M1 phenotype via the NOX2/Src/MAPK axis (244). Moreover, epigenetic regulation has emerged as a novel target; for instance, METTL3 influences immune infiltration and activation by modulating m6A RNA methylation and cholesterol biosynthesis, thereby providing a route to counter immune evasion in NASH-related HCC (245).
6.2 Metabolic and immune crosstalk research
A comprehensive understanding of the pathophysiology and progression of NAFLD and its advanced form, NASH, necessitates elucidation of the intricate crosstalk between metabolic and immune networks (246, 247). This bidirectional interplay governs immune cell activation, disrupts metabolic equilibrium, and drives hepatic microenvironmental remodeling—hallmarks underpinning disease advancement and the eventual emergence of HCC (132, 137, 248). Recent insights from multi-omics and single-cell transcriptomic analyses have delineated how host metabolic circuitry intersects with immunological pathways (249, 250). In particular, gut microbiota-derived metabolites have emerged as pivotal regulators of intrahepatic immune tone and metabolic homeostasis (251, 252). Perturbations in host–microbiota dynamics—culminating in impaired mitophagy—engender a proinflammatory hepatic niche that accelerates NAFLD progression (253). Notably, transcriptional alterations in genes governing energy metabolism and immune modulation—across macrophages, monocytes, hepatocytes, and endothelial cells—are linked to the microbial shift from symbiotic taxa (Escherichia coli in healthy individuals) to pathogenic lineages (Sphingomonadales) in NAFLD and NASH (253). The disruption of host–bacteria interactions involving key mitophagy regulators such as SQSTM1, OPTN, and BNIP3L in NASH exemplifies how metabolic collapse and immune dysfunction synergistically amplify hepatic inflammation (253, 254).
Gut microbiota-derived metabolites—including short-chain fatty acids (SCFAs), secondary bile acids (BAs), and tryptophan derivatives—serve as key signaling mediators that modulate immune cell function and hepatic metabolic circuits. SCFAs, for example, promote immunological tolerance and energy homeostasis through G-protein-coupled receptors, whereas dysbiosis-associated alterations in BA profiles perturb farnesoid X receptor (FXR) signaling, disrupting metabolic and immune equilibrium. Perturbation of BA metabolism and downstream signaling cascades contributes to hepatic steatosis, inflammation, and fibrosis, underscoring the dual immunometabolic regulatory roles of these pathways in liver disease (255–257). In NAFLD, immune cells, such as macrophages, T cells, and B cells, undergo cellular metabolic reprogramming that affects their activation, polarization, and effector functions. The altered lipid metabolism and programmed cell death pathways observed in macrophages in the liver and adipose tissue influence inflammatory responses and lead to persistent low-grade inflammation, a hallmark of metabolic liver disease. Metabolic changes determine the pro- or anti-inflammatory phenotypes of T cells, and CD4+ T cell development and function are significantly influenced by lipid metabolism. B cells, through antibody production and cytokine secretion, also participate in orchestrating hepatic immunometabolism and energy regulation (258–260).
Nucleotide-binding domain leucine-rich repeat receptors (NLRs) and the cGAS-STING pathway are examples of intracellular innate immune sensors that combine immune activation with metabolic signals. Mitochondrial stress and metabolic imbalance stimulate the cGAS-STING axis, which sets off proinflammatory cascades that worsen insulin resistance and the advancement of non-alcoholic fatty liver disease. NLR inflammasomes affect immunological responses and metabolic balance through interactions with the gut microbiota and metabolic pathways (261–263). Moreover, nuclear receptors, such as peroxisome proliferator-activated receptors (PPARs) and FXR, operate as molecular links between immune control, metabolism, and gut microbiota. These receptors coordinate the gut-liver axis and maintain hepatic homeostasis by regulating gene expression associated with immune cell activation, autophagy, and lipid and glucose metabolism. Their therapeutic potential is highlighted by the fact that dysregulation of these nuclear receptor pathways leads to immune-mediated liver damage and metabolic dysfunction (256, 264).
Therapeutic approaches that target the metabolic-immune interface are being investigated. These include pharmaceutical drugs that target immunological checkpoints and metabolic pathways, as well as modifications to gut microbiota composition via probiotics, prebiotics, and fecal microbiota transplantation (FMT). Compounds like digoxin and helveticoside, which influence metabolic reprogramming and immune cell infiltration, have demonstrated therapeutic potential in NAFLD models. Novel targets such as TM4SF5, a regulator of immune cell interactions and nutrient transport in hepatocytes, further expand the therapeutic landscape. Hepatic inflammation and fibrosis may be reduced by modifying the NLRP3 inflammasome and cGAS-STING signaling (85, 265, 266).
In sum, the pathogenesis of NAFLD and related liver diseases arises from tightly interwoven metabolic and immune dysregulation, orchestrated through host–microbiota interactions and cellular reprogramming. Elucidating these interconnected pathways paves the way for integrated therapeutic strategies that target both arms of the disease process, offering a rational framework to curb disease progression and improve clinical outcomes (251, 267) (Table 2).
Table 2. Therapeutic strategies for NASH-associated hepatocellular carcinoma (HCC).
7 Conclusion
Hepatic inflammation, fibrogenesis, and carcinogenesis are all fueled by the intricate, reciprocal interactions between immune dysregulation and metabolic dysfunction, as evidenced by the expanding body of studies on NASH-associated HCC. In the past, immunological disruptions involving T cells, macrophages, and natural killer cells, as well as metabolic changes such as insulin resistance, lipid buildup, and mitochondrial dysfunction, were studied separately. Emerging data, however, show that they are interdependent: immune cells worsen metabolic stress and fibrosis, while metabolic disturbances alter immune cell morphologies, resulting in a vicious cycle of liver damage and tumor development. This convergence not only reveals new therapeutic vulnerabilities but also advances our mechanistic understanding of disease development. Despite these developments, finding biomarkers and generalizing treatments is made more difficult by the significant variability in patient immune-metabolic profiles. The inability of preclinical models to accurately replicate the complexity of human disease underscores the need for integrated systems biology approaches, such as multi-omics and longitudinal research, to elucidate the spatiotemporal dynamics of the hepatic microenvironment.
To accelerate clinical translation, future studies should focus on identifying metabolic signatures and circulating biomarkers that can predict response to immunotherapies, particularly immune checkpoint inhibitors. Furthermore, targeting specific immunometabolic axes—such as PPARα-mediated macrophage polarization, lactate-driven M2-like TAM programming, or SIRT1/PGC-1α signaling—holds promise for restoring immune surveillance and rebalancing hepatic metabolism. Equally important is the integration of microbiome-based strategies, including fecal microbiota transplantation and metabolite modulation (SCFAs, bile acids), to reshape the gut–liver–immune axis and enhance therapy responsiveness. To restore homeostasis and anti-tumor immunity, combinatorial strategies—which mix metabolic modulators with immunotherapies like checkpoint inhibitors have gained attention due to the therapeutic awareness of immune-metabolic interaction. It’s still difficult to optimize these regimens, especially when hepatic impairment is present in advanced illness. Ultimately, a precision medicine framework that integrates immune, metabolic, and microbiome-derived data will be essential for stratifying patients and tailoring therapeutic interventions. To improve outcomes in NASH-associated HCC and advance precision medicine, a multidisciplinary, patient-specific paradigm that incorporates immunological and metabolic insights will be crucial.
Author contributions
LL: Conceptualization, Funding acquisition, Writing – original draft, Writing – review & editing. XD: Conceptualization, Methodology, Writing – original draft. BJ: Conceptualization, Funding acquisition, Methodology, Writing – original draft.
Funding
The author(s) declared that financial support was received for this work and/or its publication. This review was supported by following grands: 1. 2019 Key Support Program for Scientific and Technological Innovation Bases in Liaoning Province, Key Laboratory for Basic Research on Syndrome Differentiation and Treatment in Traditional Chinese Medicine of Liaoning Province, No. 409. 2. Liaoning Provincial Social Science Planning Fund Youth Project: Research on the Guarantee Mechanism for Promoting Community-Integrated Medical and Elderly Care Services Led by Traditional Chinese Medicine, No. L22CGL022. 3. 2025 Science and Technology Innovation Think Tank Project of Liaoning Provincial Association for Science and Technology: Research on the Guarantee Mechanism of Traditional Chinese Medicine Empowering Community-Integrated Medical and Elderly Care Services, No. LNKX2025QN09 (2025 annual achievement of Science and Technology Innovation Think Tank Project of Liaoning Provincial Association for Science and Technology). 4. Humanities and Social Sciences Research Project of Liaoning University of Traditional Chinese Medicine: Research on Countermeasures for the Integration of Medical and Elderly Care Model in Shenyang Based on Traditional Chinese Medicine Industry, No. 2019-lnzy010. 5. Shenyang Social Science Project: Research on Countermeasures to Expand the Influence of TCM Culture under the Guidance of Huangdi Neijing, No. SYSK2023-01-220.
Conflict of interest
The authors declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Motta BM, Masarone M, Torre P, and Persico M. From non-alcoholic steatohepatitis (NASH) to hepatocellular carcinoma (HCC): epidemiology, incidence, predictions, risk factors, and prevention. Cancers (Basel). (2023) 15:5458. doi: 10.3390/cancers15225458
2. Samy AM, Kandeil MA, Sabry D, Abdel-Ghany AA, and Mahmoud MO. From NAFLD to NASH: Understanding the spectrum of non-alcoholic liver diseases and their consequences. Heliyon. (2024) 10:e30387. doi: 10.1016/j.heliyon.2024.e30387
3. Craciun A and Cortez-Pinto H. Alarming increase of NASH as cause of liver cancer. Cell Rep Med. (2022) 3:100723. doi: 10.1016/j.xcrm.2022.100723
4. Bhandari P, Sapra A, Ajmeri MS, Albers CE, and Sapra D. Nonalcoholic fatty liver disease: could it be the next medical tsunami? Cureus. (2022) 14:e23806. doi: 10.7759/cureus.23806
5. Juanola O, Martínez-López S, Francés R, and Gómez-Hurtado I. Non-alcoholic fatty liver disease: metabolic, genetic, epigenetic and environmental risk factors. Int J Environ Res Public Health. (2021) 18:2890–9. doi: 10.3390/ijerph18105227
6. Lequoy M, Gigante E, Couty J-P, and Desbois-Mouthon C. Hepatocellular carcinoma in the context of non-alcoholic steatohepatitis (NASH): recent advances in the pathogenic mechanisms. Horm Mol Biol Clin Investig. (2020) 41:20190044. doi: 10.1515/hmbci-2019-0044
7. Vetrano E, Rinaldi L, Mormone A, Giorgione C, Galiero R, Caturano A, et al. Non-alcoholic fatty liver disease (NAFLD), type 2 diabetes, and non-viral hepatocarcinoma: pathophysiological mechanisms and new therapeutic strategies. Biomedicines. (2023) 11:468–87. doi: 10.3390/biomedicines11020468
8. Zhai X, Xia Z, Du G, Zhang X, Xia T, Ma D, et al. LRP1B suppresses HCC progression through the NCSTN/PI3K/AKT signaling axis and affects doxorubicin resistance. Genes Dis. (2023) 10:2082–96. doi: 10.1016/j.gendis.2022.10.021
9. Zou H, Ge Y, Lei Q, Ung COL, Ruan Z, Lai Y, et al. Epidemiology and disease burden of non-alcoholic steatohepatitis in greater China: a systematic review. Hepatol Int. (2022) 16:27–37. doi: 10.1007/s12072-021-10286-4
10. Tapper EB, Fleming C, Rendon A, Fernandes J, Johansen P, Augusto M, et al. The burden of nonalcoholic steatohepatitis: A systematic review of epidemiology studies. Gastro Hep Adv. (2022) 1:1049–87. doi: 10.1016/j.gastha.2022.06.016
11. Eguchi Y, Wong G, Lee EIH, Akhtar O, Lopes R, and Sumida Y. Epidemiology of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Japan: A focused literature review. JGH Open. (2020) 4:808–17. doi: 10.1002/jgh3.12349
12. Jothimani D, Danielraj S, Narasimhan G, Kaliamoorthy I, Rajakumar A, Palaniappan K, et al. Nonalcoholic steatohepatitis: A rapidly increasing indication for liver transplantation in India. J Clin Exp Hepatol. (2022) 12:908–16. doi: 10.1016/j.jceh.2021.09.017
13. Di Ciaula A, Passarella S, Shanmugam H, Noviello M, Bonfrate L, Wang DQH, et al. Nonalcoholic fatty liver disease (NAFLD). Mitochondria as players and targets of therapies? Int J Mol Sci. (2021) 22:5375–421. doi: 10.3390/ijms22105375
14. Oh S-H, Lee M-S, and Lee B-C. Geniposide mitigates insulin resistance and hepatic fibrosis via insulin signaling pathway. Int J Mol Sci. (2025) 26:8079–94. doi: 10.3390/ijms26168079
15. Ochoa-Rios S, O’Connor IP, Kent LN, Clouse JM, Hadjiyannis Y, Koivisto C, et al. Imaging mass spectrometry reveals alterations in N-linked glycosylation that are associated with histopathological changes in nonalcoholic steatohepatitis in mouse and human. Mol Cell Proteomics. (2022) 21:100225. doi: 10.1016/j.mcpro.2022.100225
16. Xi J, Lei S, Chen J, Liu J, Shan C, Sun X, et al. Killing hepatocellular carcinoma in the NAFLD/NASH stage: a comprehensive perspective on targeting regulated cell death. Cell Death Discov. (2025) 11:281. doi: 10.1038/s41420-025-02558-x
17. Padelli M, Hamelin J, Desterke C, Sebagh M, Saffroy R, Sanchez CG, et al. Analysis of the mitochondrial dynamics in NAFLD: drp1 as a marker of inflammation and fibrosis. Int J Mol Sci. (2025) 26:7373–85. doi: 10.3390/ijms26157373
18. Carter JK and Friedman SL. Hepatic stellate cell-immune interactions in NASH. Front Endocrinol (Lausanne). (2022) 13:867940. doi: 10.3389/fendo.2022.867940
19. Luci C, Bourinet M, Leclère PS, Anty R, and Gual P. Chronic inflammation in non-alcoholic steatohepatitis: molecular mechanisms and therapeutic strategies. Front Endocrinol (Lausanne). (2020) 11:597648. doi: 10.3389/fendo.2020.597648
20. Tan PK, Ostertag T, Rosenthal SB, Chilin-Fuentes D, Aidnik H, Linker S, et al. Role of hepatic stellate and liver sinusoidal endothelial cells in a human primary cell three-dimensional model of nonalcoholic steatohepatitis. Am J Pathol. (2024) 194:353–68. doi: 10.1016/j.ajpath.2023.12.005
21. Chen Y and Tian Z. Roles of hepatic innate and innate-like lymphocytes in nonalcoholic steatohepatitis. Front Immunol. (2020) 11:1500. doi: 10.3389/fimmu.2020.01500
22. Xu M, Xu H, Ling Y-W, Liu J-J, Song P, Fang Z-Q, et al. Neutrophil extracellular traps-triggered hepatocellular senescence exacerbates lipotoxicity in non-alcoholic steatohepatitis. J Adv Res. (2025) 79:521–34. doi: 10.1016/j.jare.2025.03.015
23. Hirsova P, Bamidele AO, Wang H, Povero D, and Revelo XS. Emerging roles of T cells in the pathogenesis of nonalcoholic steatohepatitis and hepatocellular carcinoma. Front Endocrinol (Lausanne). (2021) 12:760860. doi: 10.3389/fendo.2021.760860
24. Dudek M, Pfister D, Donakonda S, Filpe P, Schneider A, Laschinger M, et al. Auto-aggressive CXCR6(+) CD8 T cells cause liver immune pathology in NASH. Nature. (2021) 592:444–9. doi: 10.1038/s41586-021-03233-8
25. Chen X, Wang D, Wang Z, and Huang W. Identification of pyroptosis-related genes in NASH based on bioinformatic analysis. Biochem Biophys Res Commun. (2023) 679:90–7. doi: 10.1016/j.bbrc.2023.08.067
26. Wei S, Wang L, Evans PC, and Xu S. NAFLD and NASH: etiology, targets and emerging therapies. Drug Discov Today. (2024) 29:103910. doi: 10.1016/j.drudis.2024.103910
27. Sobhia ME, Kumari S, Kumar H, Gandhe A, Kaushik D, Kumar H, et al. Emerging therapies and therapeutic targets for composite liver disease: NASH. Curr Top Med Chem. (2023) 23:2027–47. doi: 10.2174/1568026623666230714113808
28. Li H, Zhou Y, Wang H, Zhang M, Qiu P, Zhang M, et al. Crosstalk between liver macrophages and surrounding cells in nonalcoholic steatohepatitis. Front Immunol. (2020) 11:1169. doi: 10.3389/fimmu.2020.01169
29. Padmanaban S, Baek J-W, Chamarthy SS, Chandrasekaran S, Samrot AV, Gosu V, et al. Nanoparticle-based therapeutic strategies for chronic liver diseases: Advances and insights. Liver Res. (2025) 9:104–17. doi: 10.1016/j.livres.2025.04.002
30. Seike T, Mizukoshi E, Yamada K, Okada H, Kitahara M, Yamashita T, et al. Fatty acid-driven modifications in T-cell profiles in non-alcoholic fatty liver disease patients. J Gastroenterol. (2020) 55:701–11. doi: 10.1007/s00535-020-01679-7
31. Riaz F, Wei P, and Pan F. Fine-tuning of regulatory T cells is indispensable for the metabolic steatosis-related hepatocellular carcinoma: A review. Front Cell Dev Biol. (2022) 10:949603. doi: 10.3389/fcell.2022.949603
32. Ortiz-López N, Fuenzalida C, Dufeu MS, Pinto-León A, Escobar A, Poniachik J, et al. The immune response as a therapeutic target in non-alcoholic fatty liver disease. Front Immunol. (2022) 13:954869. doi: 10.3389/fimmu.2022.954869
33. Zhang H, Xia T, Xia Z, Zhou H, Li Z, Wang W, et al. KIF18A inactivates hepatic stellate cells and alleviates liver fibrosis through the TTC3/Akt/mTOR pathway. Cell Mol Life Sci. (2024) 81:96. doi: 10.1007/s00018-024-05114-5
34. Czaja AJ. Incorporating mucosal-associated invariant T cells into the pathogenesis of chronic liver disease. World J Gastroenterol. (2021) 27:3705–33. doi: 10.3748/wjg.v27.i25.3705
35. Kedia-Mehta N and Hogan AE. MAITabolism(2) - the emerging understanding of MAIT cell metabolism and their role in metabolic disease. Front Immunol. (2022) 13:1108071. doi: 10.3389/fimmu.2022.1108071
36. Lukasik Z, Elewaut D, and Venken K. MAIT cells come to the rescue in cancer immunotherapy? Cancers (Basel). (2020) 12:413–21. doi: 10.3390/cancers12020413
37. Huang W, He W, Shi X, He X, Dou L, and Gao Y. The role of CD1d and MR1 restricted T cells in the liver. Front Immunol. (2018) 9:2424. doi: 10.3389/fimmu.2018.02424
38. Lett MJ, Mehta H, Keogh A, Jaeger T, Jacquet M, Powell K, et al. Stimulatory MAIT cell antigens reach the circulation and are efficiently metabolised and presented by human liver cells. Gut. (2022) 71:2526–38. doi: 10.1136/gutjnl-2021-324478
39. Deschler S, Pohl-Topcu J, Ramsauer L, Meiser P, Erlacher S, Schenk RP, et al. Polyunsaturated fatty acid-induced metabolic exhaustion and ferroptosis impair the anti-tumour function of MAIT cells in MASLD. J Hepatol. (2025) 83:1364–78. doi: 10.1016/j.jhep.2025.06.006
40. Zeng F, Zhang Y, Han X, Zeng M, Gao Y, and Weng J. Predicting non-alcoholic fatty liver disease progression and immune deregulations by specific gene expression patterns. Front Immunol. (2020) 11:609900. doi: 10.3389/fimmu.2020.609900
41. Hammerich L and Tacke F. Role of gamma-delta T cells in liver inflammation and fibrosis. World J Gastrointest Pathophysiol. (2014) 5:107–13. doi: 10.4291/wjgp.v5.i2.107
42. Zhan C, Peng C, Wei H, Wei K, Ou Y, and Zhang Z. Diverse subsets of γδT cells and their specific functions across liver diseases. Int J Mol Sci. (2025) 26:2778–809. doi: 10.3390/ijms26062778
43. Waickman AT and Powell JD. mTOR, metabolism, and the regulation of T-cell differentiation and function. Immunol Rev. (2012) 249:43–58. doi: 10.1111/j.1600-065X.2012.01152.x
44. Yang Q, Liu X, Liu Q, Guan Z, Luo J, Cao G, et al. Roles of mTORC1 and mTORC2 in controlling γδ T1 and γδ T17 differentiation and function. Cell Death Differ. (2020) 27:2248–62. doi: 10.1038/s41418-020-0500-9
45. Hu C, Xu B, Wang X, Wan WH, Lu J, Kong D, et al. Gut microbiota-derived short-chain fatty acids regulate group 3 innate lymphoid cells in HCC. Hepatology. (2023) 77:48–64. doi: 10.1002/hep.32449
46. Fachi JL, Pral LP, Dos Santos JAC, Codo AC, de Oliveira S, Felipe JS, et al. Hypoxia enhances ILC3 responses through HIF-1α-dependent mechanism. Mucosal Immunol. (2021) 14:828–41. doi: 10.1038/s41385-020-00371-6
47. Zhou Q-H, Wu F-T, Pang L-T, Zhang T-B, and Chen Z. Role of γδT cells in liver diseases and its relationship with intestinal microbiota. World J Gastroenterol. (2020) 26:2559–69. doi: 10.3748/wjg.v26.i20.2559
48. Cuff AO, Sillito F, Dertschnig S, Hall A, Luong TV, Chakraverty R, et al. The obese liver environment mediates conversion of NK cells to a less cytotoxic ILC1-like phenotype. Front Immunol. (2019) 10:2180. doi: 10.3389/fimmu.2019.02180
49. Abdelnabi MN, Hassan GS, and Shoukry NH. Role of the type 3 cytokines IL-17 and IL-22 in modulating metabolic dysfunction-associated steatotic liver disease. Front Immunol. (2024) 15:1437046. doi: 10.3389/fimmu.2024.1437046
50. Luci C, Vieira E, Perchet T, Gual P, and Golub R. Natural killer cells and type 1 innate lymphoid cells are new actors in non-alcoholic fatty liver disease. Front Immunol. (2019) 10:1192. doi: 10.3389/fimmu.2019.01192
51. Chen H, Sun L, Feng L, Yin Y, and Zhang W. Role of innate lymphoid cells in obesity and insulin resistance. Front Endocrinol (Lausanne). (2022) 13:855197. doi: 10.3389/fendo.2022.855197
52. Martínez-Chantar ML, Delgado TC, and Beraza N. Revisiting the role of natural killer cells in non-alcoholic fatty liver disease. Front Immunol. (2021) 12:640869. doi: 10.3389/fimmu.2021.640869
53. Diedrich T, Kummer S, Galante A, Drolz A, Schlicker V, Lohse AW, et al. Characterization of the immune cell landscape of patients with NAFLD. PloS One. (2020) 15:e0230307. doi: 10.1371/journal.pone.0230307
54. Gu X, Chu Q, Ma X, Wang J, Chen C, Guan J, et al. New insights into iNKT cells and their roles in liver diseases. Front Immunol. (2022) 13:1035950. doi: 10.3389/fimmu.2022.1035950
55. Ibrahim SH. Sinusoidal endotheliopathy in nonalcoholic steatohepatitis: therapeutic implications. Am J Physiol Gastrointest Liver Physiol. (2021) 321:G67–74. doi: 10.1152/ajpgi.00009.2021
56. Wang F, Cui Q, Zeng Y, and Chen P. Gut microbiota-an important contributor to liver diseases. Nan Fang Yi Ke Da Xue Xue Bao. (2020) 40:595–600. doi: 10.12122/j.issn.1673-4254.2020.04.23
57. Yu SY and Xu L. The interplay between host cellular and gut microbial metabolism in NAFLD development and prevention. J Appl Microbiol. (2021) 131:564–82. doi: 10.1111/jam.14992
58. Kim CH, Park J, and Kim M. Gut microbiota-derived short-chain Fatty acids, T cells, and inflammation. Immune Netw. (2014) 14:277–88. doi: 10.4110/in.2014.14.6.277
59. Visekruna A and Luu M. The role of short-chain fatty acids and bile acids in intestinal and liver function, inflammation, and carcinogenesis. Front Cell Dev Biol. (2021) 9:703218. doi: 10.3389/fcell.2021.703218
60. Fleishman JS and Kumar S. Bile acid metabolism and signaling in health and disease: molecular mechanisms and therapeutic targets. Signal Transduct Target Ther. (2024) 9:97. doi: 10.1038/s41392-024-01811-6
61. Du HX, Yue SY, Niu D, Liu C, Zhang LG, Chen J, et al. Gut microflora modulates th17/treg cell differentiation in experimental autoimmune prostatitis via the short-chain fatty acid propionate. Front Immunol. (2022) 13:915218. doi: 10.3389/fimmu.2022.915218
62. Yan W, Zhang K, Guo J, and Xu L. Bile acid-mediated gut-liver axis crosstalk: the role of nuclear receptor signaling in dynamic regulation of inflammatory networks. Front Immunol. (2025) 16:1595486. doi: 10.3389/fimmu.2025.1595486
63. Guo Y, Zhang N, and Pei D. Gut microbiota heterogeneity in non-alcoholic fatty liver disease: a narrative review of drivers, mechanisms, and clinical relevance. Front Microbiol. (2025) 16:1645298. doi: 10.3389/fmicb.2025.1645298
64. Pallozzi M, De Gaetano V, Di Tommaso N, Cerrito L, Santopaolo F, Stella L, et al. Role of gut microbial metabolites in the pathogenesis of primary liver cancers. Nutrients. (2024) 16:2372–96. doi: 10.3390/nu16142372
65. Luo W, Li R, Pan C, and Luo C. Gut microbiota-derived metabolites in immunomodulation and gastrointestinal cancer immunotherapy. Front Immunol. (2025) 16:1710880. doi: 10.3389/fimmu.2025.1710880
66. Xie H, Xi X, Lei T, Liu H, and Xia Z. CD8(+) T cell exhaustion in the tumor microenvironment of breast cancer. Front Immunol. (2024) 15:1507283. doi: 10.3389/fimmu.2024.1507283
67. Deng Y, Shi M, Yi L, Naveed Khan M, Xia Z, and Li X. Eliminating a barrier: Aiming at VISTA, reversing MDSC-mediated T cell suppression in the tumor microenvironment. Heliyon. (2024) 10:e37060. doi: 10.1016/j.heliyon.2024.e37060
68. Huang Y, Liu X, Wang H-Y, Chen J-Y, Zhang X, Li Y, et al. Single-cell transcriptome landscape of zebrafish liver reveals hepatocytes and immune cell interactions in understanding nonalcoholic fatty liver disease. Fish Shellfish Immunol. (2024) 146:109428. doi: 10.1016/j.fsi.2024.109428
69. Hundertmark J, Berger H, and Tacke F. Single cell RNA sequencing in NASH. Methods Mol Biol. (2022) 2455:181–202. doi: 10.1007/978-1-0716-2128-8_15
70. Zhang H, Zhai X, Liu Y, Xia Z, Xia T, Du G, et al. NOP2-mediated m5C Modification of c-Myc in an EIF3A-Dependent Manner to Reprogram Glucose Metabolism and Promote Hepatocellular Carcinoma Progression. Res (Wash D C). (2023) 6:0184. doi: 10.34133/research.0184
71. Lee J-L, Wang Y-C, Hsu Y-A, Chen C-S, Weng R-C, Lu Y-P, et al. Galectin-12 modulates Kupffer cell polarization to alter the progression of nonalcoholic fatty liver disease. Glycobiology. (2023) 33:673–82. doi: 10.1093/glycob/cwad062
72. Fujii H, Kawada N, and Japan SGON. The role of insulin resistance and diabetes in nonalcoholic fatty liver disease. Int J Mol Sci. (2020) 21:3863–80. doi: 10.3390/ijms21113863
73. Zhai X, Zhang H, Xia Z, Liu M, Du G, Jiang Z, et al. Oxytocin alleviates liver fibrosis via hepatic macrophages. JHEP Rep. (2024) 6:101032. doi: 10.1016/j.jhepr.2024.101032
74. Parthasarathy G and Revelo X. Malhi H: pathogenesis of nonalcoholic steatohepatitis: an overview. Hepatol Commun. (2020) 4:478–92. doi: 10.1002/hep4.1479
75. Chen Y and Tian Z. Innate lymphocytes: pathogenesis and therapeutic targets of liver diseases and cancer. Cell Mol Immunol. (2021) 18:57–72. doi: 10.1038/s41423-020-00561-z
76. Chaudhary S, Rai R, Pal PB, Tedesco D, Singhi AD, Monga SP, et al. Western diet dampens T regulatory cell function to fuel hepatic inflammation in nonalcoholic fatty liver disease. bioRxiv. (2023). doi: 10.1101/2023.03.23.533977
77. Sun G, Wei Y, Zhu J, Zheng S, Zhang Z, and Zhang D. The transcription factor T-bet promotes the pathogenesis of nonalcoholic fatty liver disease by upregulating intrahepatic inflammation. Biochem Biophys Res Commun. (2023) 682:266–73. doi: 10.1016/j.bbrc.2023.10.014
78. Myint M, Oppedisano F, De Giorgi V, Kim B-M, Marincola FM, Alter HJ, et al. Inflammatory signaling in NASH driven by hepatocyte mitochondrial dysfunctions. J Transl Med. (2023) 21:757. doi: 10.1186/s12967-023-04627-0
79. Liu T, Xu G, Liang L, Xiao X, Zhao Y, and Bai Z. Pharmacological effects of Chinese medicine modulating NLRP3 inflammasomes in fatty liver treatment. Front Pharmacol. (2022) 13:967594. doi: 10.3389/fphar.2022.967594
80. Guo Z, Fan X, Yao J, Tomlinson S, Yuan G, and He S. The role of complement in nonalcoholic fatty liver disease. Front Immunol. (2022) 13:1017467. doi: 10.3389/fimmu.2022.1017467
81. Shao L, Song Y, and Shi JP. Role of gut-liver-immune axis in the pathogenesis of nonalcoholic steatohepatitis. Zhonghua Gan Zang Bing Za Zhi. (2021) 29:505–9.
82. Wu H, Lei Y, and Mao J. Non-alcoholic fatty liver disease and intestinal immune status: a narrative review. Scand J Gastroenterol. (2022) 57:642–9. doi: 10.1080/00365521.2022.2032320
83. Hammerich L and Tacke F. Hepatic inflammatory responses in liver fibrosis. Nat Rev Gastroenterol Hepatol. (2023) 20:633–46. doi: 10.1038/s41575-023-00807-x
84. Lebeaupin C, Proics E, de Bieville CH, Rousseau D, Bonnafous S, Patouraux S, et al. ER stress induces NLRP3 inflammasome activation and hepatocyte death. Cell Death Dis. (2015) 6:e1879. doi: 10.1038/cddis.2015.248
85. Yu T, Luo L, Xue J, Tang W, Wu X, and Yang F. Gut microbiota-NLRP3 inflammasome crosstalk in metabolic dysfunction-associated steatotic liver disease. Clin Res Hepatol Gastroenterol. (2024) 48:102458. doi: 10.1016/j.clinre.2024.102458
86. Blevins HM, Xu Y, Biby S, and Zhang S. The NLRP3 inflammasome pathway: A review of mechanisms and inhibitors for the treatment of inflammatory diseases. Front Aging Neurosci. (2022) 14:879021. doi: 10.3389/fnagi.2022.879021
87. Mridha AR, Wree A, Robertson AAB, Yeh MM, Johnson CD, Van Rooyen DM, et al. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice. J Hepatol. (2017) 66:1037–46. doi: 10.1016/j.jhep.2017.01.022
88. Yu L, Hong W, Lu S, Li Y, Guan Y, Weng X, et al. The NLRP3 inflammasome in non-alcoholic fatty liver disease and steatohepatitis: therapeutic targets and treatment. Front Pharmacol. (2022) 13:780496. doi: 10.3389/fphar.2022.780496
89. Zheng Y, Sun J, Luo Z, Li Y, and Huang Y. Emerging mechanisms of lipid peroxidation in regulated cell death and its physiological implications. Cell Death Dis. (2024) 15:859. doi: 10.1038/s41419-024-07244-x
90. Abais JM, Xia M, Zhang Y, Boini KM, and Li PL. Redox regulation of NLRP3 inflammasomes: ROS as trigger or effector? Antioxid Redox Signal. (2015) 22:1111–29. doi: 10.1089/ars.2014.5994
91. Sun H and Kemper JK. MicroRNA regulation of AMPK in nonalcoholic fatty liver disease. Exp Mol Med. (2023) 55:1974–81. doi: 10.1038/s12276-023-01072-3
92. Puengel T, Liu H, Guillot A, Heymann F, Tacke F, and Peiseler M. Nuclear receptors linking metabolism, inflammation, and fibrosis in nonalcoholic fatty liver disease. Int J Mol Sci. (2022) 23:2668–95. doi: 10.3390/ijms23052668
93. Wiering L and Tacke F. Treating inflammation to combat non-alcoholic fatty liver disease. J Endocrinol. (2023) 256:e220194–214. doi: 10.1530/JOE-22-0194
94. Wang L, Yang Y, Sun H, and Fei M. Magnoflorine alleviates nonalcoholic fatty liver disease by modulating lipid metabolism, mitophagy and inflammation. Prostaglandins Other Lipid Mediat. (2025) 178:106997. doi: 10.1016/j.prostaglandins.2025.106997
95. Ma X, Zhang W, Jiang Y, Wen J, Wei S, and Zhao Y. Paeoniflorin, a natural product with multiple targets in liver diseases-A mini review. Front Pharmacol. (2020) 11:531. doi: 10.3389/fphar.2020.00531
96. Liu M, Zhang P, and Lyu X. Research progress of metabolism reprogramming in regulating macrophage polarization. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. (2020) 32:765–8. doi: 10.3760/cma.j.cn121430-20200211-00177
97. Zhao F, Yue Z, Zhang L, Qi Y, Sun Y, Wang S, et al. Emerging advancements in metabolic properties of macrophages within disease microenvironment for immune therapy. J Innate Immun. (2025) 17:320–40. doi: 10.1159/000546476
98. Xiong Y, Zhou J, Wang J, and Huang H. How lactate and lactylation shape the immunity system in atherosclerosis (Review). Int J Mol Med. (2025) 56:163–77. doi: 10.3892/ijmm.2025.5604
99. Tian L-R, Lin M-Z, Zhong H-H, Cai Y-J, Li B, Xiao Z-C, et al. Nanodrug regulates lactic acid metabolism to reprogram the immunosuppressive tumor microenvironment for enhanced cancer immunotherapy. Biomater Sci. (2022) 10:3892–900. doi: 10.1039/D2BM00650B
100. Lin R, Zhu Y, Liu Y, Guo Z, Wei J, Li Y, et al. Sirtuins regulate macrophage polarization in heart failure: Metabolic reprogramming, epigenetic regulation, and immune cell interactions. Pharmacol Res. (2025) 220:107936. doi: 10.1016/j.phrs.2025.107936
101. Jiang P and Li X. Regulatory mechanism of lncRNAs in M1/M2 macrophages polarization in the diseases of different etiology. Front Immunol. (2022) 13:835932. doi: 10.3389/fimmu.2022.835932
102. Shan X, Hu P, Ni L, Shen L, Zhang Y, Ji Z, et al. Serine metabolism orchestrates macrophage polarization by regulating the IGF1-p38 axis. Cell Mol Immunol. (2022) 19:1263–78. doi: 10.1038/s41423-022-00925-7
103. Xue L, Wang C, Qian Y, Zhu W, Liu L, Yang X, et al. Tryptophan metabolism regulates inflammatory macrophage polarization as a predictive factor for breast cancer immunotherapy. Int Immunopharmacol. (2023) 125:111196. doi: 10.1016/j.intimp.2023.111196
104. Li M, Lan F, Li C, Li N, Chen X, Zhong Y, et al. Expression and regulation network of HDAC3 in acute myeloid leukemia and the implication for targeted therapy based on multidataset data mining. Comput Math Methods Med. (2022) 2022:4703524. doi: 10.1155/2022/4703524
105. Li C, Li J, Li X, Sha Y, and Ren W. Research progress on the functional polarization mechanism of myeloid-derived cells in the tumor microenvironment and their targeted therapy potential. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. (2025) 41:844–50. doi: 10.13423/j.cnki.cjcmi.009974
106. Armandi A, Rosso C, Caviglia GP, and Bugianesi E. Insulin resistance across the spectrum of nonalcoholic fatty liver disease. Metabolites. (2021) 11:155–70. doi: 10.3390/metabo11030155
107. Song K, Kim H-S, and Chae HW. Nonalcoholic fatty liver disease and insulin resistance in children. Clin Exp Pediatr. (2023) 66:512–9. doi: 10.3345/cep.2022.01312
108. Ota T. Molecular mechanisms of nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH). Adv Exp Med Biol. (2021) 1261:223–9. doi: 10.1007/978-981-15-7360-6_20
109. Chen T, Dalton G, Oh S-H, Maeso-Diaz R, Du K, Meyers RA, et al. Hepatocyte smoothened activity controls susceptibility to insulin resistance and nonalcoholic fatty liver disease. Cell Mol Gastroenterol Hepatol. (2023) 15:949–70. doi: 10.1016/j.jcmgh.2022.12.008
110. Zhang Y, Lu QH, Cao HF, Zhang SR, and Wang HD. Effects of GPR81 agonist on insulin resistance in rats with nonalcoholic fatty liver disease. Zhongguo Ying Yong Sheng Li Xue Za Zhi. (2021) 37:354–8. doi: 10.12047/j.cjap.6055.2021.033
111. Vittal A, Shapses M, Sharma B, Sharma D, Sun Q, Sampson M, et al. Lipoprotein insulin resistance index reflects liver fat content in patients with nonalcoholic fatty liver disease. Hepatol Commun. (2021) 5:589–97. doi: 10.1002/hep4.1658
112. Pérez-Mayorga M, Lopez-Lopez JP, Chacon-Manosalva MA, Castillo MG, Otero J, Martinez-Bello D, et al. Insulin resistance markers to detect nonalcoholic fatty liver disease in a male hispanic population. Can J Gastroenterol Hepatol. (2022) 2022:1782221. doi: 10.1155/2022/1782221
113. Wu X, Wang Y, Jia Y, Liu J, and Wang G. Risk factors for nonalcoholic fatty liver disease with different insulin resistance in a nonobese chinese population. J Diabetes Res. (2022) 2022:9060405. doi: 10.1155/2022/9060405
114. Morandi A, Di Sessa A, Zusi C, Umano GR, El Mazloum D, Fornari E, et al. Nonalcoholic fatty liver disease and estimated insulin resistance in obese youth: A mendelian randomization analysis. J Clin Endocrinol Metab. (2020) 105:e4046–54. doi: 10.1210/clinem/dgaa583
115. Kakleas K, Christodouli F, and Karavanaki K. Nonalcoholic fatty liver disease, insulin resistance, and sweeteners: a literature review. Expert Rev Endocrinol Metab. (2020) 15:83–93. doi: 10.1080/17446651.2020.1740588
116. Federico A, Rosato V, Masarone M, Torre P, Dallio M, Romeo M, et al. The role of fructose in non-alcoholic steatohepatitis: old relationship and new insights. Nutrients. (2021) 13:1314–33. doi: 10.3390/nu13041314
117. Zhang C-H, Zhou B-G, Sheng J-Q, Chen Y, Cao Y-Q, and Chen C. Molecular mechanisms of hepatic insulin resistance in nonalcoholic fatty liver disease and potential treatment strategies. Pharmacol Res. (2020) 159:104984. doi: 10.1016/j.phrs.2020.104984
118. Isaacs S. Nonalcoholic fatty liver disease. Endocrinol Metab Clin North Am. (2023) 52:149–64. doi: 10.1016/j.ecl.2022.06.007
119. Fang C, Pan J, Qu N, Lei Y, Han J, Zhang J, et al. The AMPK pathway in fatty liver disease. Front Physiol. (2022) 13:970292. doi: 10.3389/fphys.2022.970292
120. Liu X-H, Qi L-W, Alolga RN, and Liu Q. Implication of the hepatokine, fibrinogen-like protein 1 in liver diseases, metabolic disorders and cancer: The need to harness its full potential. Int J Biol Sci. (2022) 18:292–300. doi: 10.7150/ijbs.66834
121. Liu T, Xu W, Gao Q, Malik A, Tinkov AA, Ngwa AN, et al. Calcium-sensing receptor: a potential target for liver health and diseases. J Transl Med. (2025) 23:1101. doi: 10.1186/s12967-025-07182-y
122. Li M, Lv M, Liu T, Du G, and Wang Q. Lipid metabolic disorder induced by pyrethroids in nonalcoholic fatty liver disease of xenopus laevis. Environ Sci Technol. (2022) 56:8463–74. doi: 10.1021/acs.est.2c00516
123. Shin M-R, Shin SH, and Roh S-S. Diospyros kaki and Citrus unshiu Mixture Improves Disorders of Lipid Metabolism in Nonalcoholic Fatty Liver Disease. Can J Gastroenterol Hepatol. (2020) 2020:8812634. doi: 10.1155/2020/8812634
124. Gautam J, Wu J, Lally JSV, McNicol JD, Fayyazi R, Ahmadi E, et al. ACLY inhibition promotes tumour immunity and suppresses liver cancer. Nature. (2025) 645:507–17. doi: 10.1038/s41586-025-09297-0
125. Gai H, Zhou F, Zhang Y, Ai J, Zhan J, You Y, et al. Coniferaldehyde ameliorates the lipid and glucose metabolism in palmitic acid-induced HepG2 cells via the LKB1/AMPK signaling pathway. J Food Sci. (2020) 85:4050–60. doi: 10.1111/1750-3841.15482
126. Ruderman NB, Xu XJ, Nelson L, Cacicedo JM, Saha AK, Lan F, et al. AMPK and SIRT1: a long-standing partnership? Am J Physiol Endocrinol Metab. (2010) 298:E751–760. doi: 10.1152/ajpendo.00745.2009
127. Anggreini P, Kuncoro H, Sumiwi SA, and Levita J. Role of the AMPK/SIRT1 pathway in non−alcoholic fatty liver disease (Review). Mol Med Rep. (2023) 27:35–46. doi: 10.3892/mmr.2022.12922
128. Flati I, Di Vito Nolfi M, Dall’Aglio F, Vecchiotti D, Verzella D, Alesse E, et al. Molecular mechanisms underpinning immunometabolic reprogramming: how the wind changes during cancer progression. Genes (Basel). (2023) 14:1953–82. doi: 10.3390/genes14101953
129. Grabacka M, Pierzchalska M, Płonka PM, and Pierzchalski P. The role of PPAR alpha in the modulation of innate immunity. Int J Mol Sci. (2021) 22:10545–71. doi: 10.3390/ijms221910545
130. Bougarne N, Weyers B, Desmet SJ, Deckers J, Ray DW, Staels B, et al. Molecular actions of PPARα in lipid metabolism and inflammation. Endocr Rev. (2018) 39:760–802. doi: 10.1210/er.2018-00064
131. Pinter M, Pinato DJ, Ramadori P, and Heikenwalder M. NASH and hepatocellular carcinoma: immunology and immunotherapy. Clin Cancer Res. (2023) 29:513–20. doi: 10.1158/1078-0432.CCR-21-1258
132. Jee YM, Lee JY, and Ryu T. Chronic inflammation and immune dysregulation in metabolic-dysfunction-associated steatotic liver disease progression: from steatosis to hepatocellular carcinoma. Biomedicines. (2025) 13:1260–82. doi: 10.3390/biomedicines13051260
133. Kim H, Park C, and Kim TH. Targeting liver X receptors for the treatment of non-alcoholic fatty liver disease. Cells. (2023) 12:1292–312. doi: 10.3390/cells12091292
134. Di Ciaula A, Calamita G, Shanmugam H, Khalil M, Bonfrate L, Wang DQH, et al. Mitochondria matter: systemic aspects of nonalcoholic fatty liver disease (NAFLD) and diagnostic assessment of liver function by stable isotope dynamic breath tests. Int J Mol Sci. (2021) 22:7702–36. doi: 10.3390/ijms22147702
135. Pu J. Targeting the lysosome: Mechanisms and treatments for nonalcoholic fatty liver disease. J Cell Biochem. (2022) 123:1624–33. doi: 10.1002/jcb.30274
136. Fujinuma S, Nakatsumi H, Shimizu H, Sugiyama S, Harada A, Goya T, et al. FOXK1 promotes nonalcoholic fatty liver disease by mediating mTORC1-dependent inhibition of hepatic fatty acid oxidation. Cell Rep. (2023) 42:112530. doi: 10.1016/j.celrep.2023.112530
137. Peiseler M, Schwabe R, Hampe J, Kubes P, Heikenwälder M, and Tacke F. Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits. J Hepatol. (2022) 77:1136–60. doi: 10.1016/j.jhep.2022.06.012
138. Ji P-X, Chen Y-X, Ni X-X, Miao Q, and Hua J. Effect of triggering receptor expressed on myeloid cells 2-associated alterations on lipid metabolism in macrophages in the development of non-alcoholic fatty liver disease. J Gastroenterol Hepatol. (2024) 39:369–80. doi: 10.1111/jgh.16417
139. Eguchi A, Iwasa M, and Nakagawa H. Extracellular vesicles in fatty liver disease and steatohepatitis: Role as biomarkers and therapeutic targets. Liver Int. (2023) 43:292–8. doi: 10.1111/liv.15490
140. Liu Y, Wu Z, Zhao Y, Zhen M, Wang Y, and Liu Q. Apolipoprotein H-based prognostic risk correlates with liver lipid metabolism disorder in patients with HBV-related hepatocellular carcinoma. Heliyon. (2024) 10:e31412. doi: 10.1016/j.heliyon.2024.e31412
141. Chen S-Y, Ni A-Y, Qian Q-H, Yan J, Wang X-D, and Wang H-L. Research progress on regulation of N(6)-adenylate methylation modification in lipid metabolism disorders. Sheng Li Xue Bao. (2023) 75:439–50. doi: 10.13294/j.aps.2023.0038
142. Fang Z, Dou G, and Wang L. MicroRNAs in the pathogenesis of nonalcoholic fatty liver disease. Int J Biol Sci. (2021) 17:1851–63. doi: 10.7150/ijbs.59588
143. Lischka J, Schanzer A, Hojreh A, Ba-Ssalamah A, de Gier C, Valent I, et al. Circulating microRNAs 34a, 122, and 192 are linked to obesity-associated inflammation and metabolic disease in pediatric patients. Int J Obes (Lond). (2021) 45:1763–72. doi: 10.1038/s41366-021-00842-1
144. Vitulo M, Gnodi E, Rosini G, Meneveri R, Giovannoni R, and Barisani D. Current therapeutical approaches targeting lipid metabolism in NAFLD. Int J Mol Sci. (2023) 24:12748–86. doi: 10.3390/ijms241612748
145. Ghavidel F, Hashemy SI, Aliari M, Rajabian A, Tabrizi MH, Atkin SL, et al. The effects of resveratrol supplementation on the metabolism of lipids in metabolic disorders. Curr Med Chem. (2025) 32:2219–34. doi: 10.2174/0109298673255218231005062112
146. Guo Y, Zhou P, Qiao L, Guan H, Gou J, and Liu X. Maternal protein deficiency impairs peroxisome biogenesis and leads to oxidative stress and ferroptosis in liver of fetal growth restriction offspring. J Nutr Biochem. (2023) 121:109432. doi: 10.1016/j.jnutbio.2023.109432
147. Mandal B, Das R, and Mondal S. Anthocyanins: Potential phytochemical candidates for the amelioration of non-alcoholic fatty liver disease. Ann Pharm Fr. (2024) 82:373–91. doi: 10.1016/j.pharma.2024.02.005
148. Wu C, Xiang S, Wang H, Zhang X, Tian X, Tan M, et al. Orally deliverable sequence-targeted fucoxanthin-loaded biomimetic extracellular vesicles for alleviation of nonalcoholic fatty liver disease. ACS Appl Mater Interfaces. (2024) 16:9854–67. doi: 10.1021/acsami.3c18029
149. Dashti Z, Yousefi Z, Kiani P, Taghizadeh M, Maleki MH, Borji M, et al. Autophagy and the unfolded protein response shape the non-alcoholic fatty liver landscape: decoding the labyrinth. Metabolism. (2024) 154:155811. doi: 10.1016/j.metabol.2024.155811
150. García-Berumen CI, Vargas-Vargas MA, Ortiz-Avila O, Piña-Zentella RM, Ramos-Gómez M, Figueroa-García MDC, et al. Avocado oil alleviates non-alcoholic fatty liver disease by improving mitochondrial function, oxidative stress and inflammation in rats fed a high fat-High fructose diet. Front Pharmacol. (2022) 13:1089130. doi: 10.3389/fphar.2022.1089130
151. Nakanishi T, Kawasaki Y, Nakamura Y, Kimura Y, Kawamura K, Shumba MN, et al. An implication of the mitochondrial carrier SLC25A3 as an oxidative stress modulator in NAFLD. Exp Cell Res. (2023) 431:113740. doi: 10.1016/j.yexcr.2023.113740
152. Li Z, Wang H, Wu K, and Zhang L. Omarigliptin protects against nonalcoholic fatty liver disease by ameliorating oxidative stress and inflammation. J Biochem Mol Toxicol. (2021) 35:e22914. doi: 10.1002/jbt.22914
153. Jorgačević B, Vučević D, Samardžić J, Mladenović D, Vesković M, Vukićević D, et al. The effect of CB1 antagonism on hepatic oxidative/nitrosative stress and inflammation in nonalcoholic fatty liver disease. Curr Med Chem. (2021) 28:169–80. doi: 10.2174/0929867327666200303122734
154. Mao T, Yang R, Luo Y, and He K. Crucial role of T cells in NAFLD-related disease: A review and prospect. Front Endocrinol (Lausanne). (2022) 13:1051076. doi: 10.3389/fendo.2022.1051076
155. Ziolkowska S, Binienda A, Jabłkowski M, Szemraj J, and Czarny P. The interplay between insulin resistance, inflammation, oxidative stress, base excision repair and metabolic syndrome in nonalcoholic fatty liver disease. Int J Mol Sci. (2021) 22:11128–55. doi: 10.3390/ijms222011128
156. Ying Y, Zhang H, Yu D, Zhang W, Zhou D, and Liu S. Gegen qinlian decoction ameliorates nonalcoholic fatty liver disease in rats via oxidative stress, inflammation, and the NLRP3 signal axis. Evid Based Complement Alternat Med. (2021) 2021:6659445. doi: 10.1155/2021/6659445
157. Ye J, Zheng J, Tian X, Xu B, Yuan F, Wang B, et al. Fucoxanthin attenuates free fatty acid-induced nonalcoholic fatty liver disease by regulating lipid metabolism/oxidative stress/inflammation via the AMPK/nrf2/TLR4 signaling pathway. Mar Drugs. (2022) 20:225–39. doi: 10.3390/md20040225
158. Yan J-B, Nie Y-M, Xu S-M, Zhang S, and Chen Z-Y. Pure total flavonoids from citrus alleviate oxidative stress and inflammation in nonalcoholic fatty liver disease by regulating the miR-137-3p/NOXA2/NOX2 pathway. Phytomedicine. (2023) 118:154944. doi: 10.1016/j.phymed.2023.154944
159. Yu Y, Tian T, Tan S, Wu P, Guo Y, Li M, et al. MicroRNA-665-3p exacerbates nonalcoholic fatty liver disease in mice. Bioengineered. (2022) 13:2927–42. doi: 10.1080/21655979.2021.2017698
160. Hernández-Bustabad A, Morales-Arraez D, González-Paredes FJ, Abrante B, Díaz-Flores F, Abreu-González P, et al. Chronic intermittent hypoxia promotes early intrahepatic endothelial impairment in rats with nonalcoholic fatty liver disease. Am J Physiol Gastrointest Liver Physiol. (2022) 323:G362–74. doi: 10.1152/ajpgi.00300.2021
161. Shree Harini K and Ezhilarasan D. Wnt/beta-catenin signaling and its modulators in nonalcoholic fatty liver diseases. Hepatobiliary Pancreat Dis Int. (2023) 22:333–45. doi: 10.1016/j.hbpd.2022.10.003
162. Takatani N, Kono Y, Beppu F, Okamatsu-Ogura Y, Yamano Y, Miyashita K, et al. Fucoxanthin inhibits hepatic oxidative stress, inflammation, and fibrosis in diet-induced nonalcoholic steatohepatitis model mice. Biochem Biophys Res Commun. (2020) 528:305–10. doi: 10.1016/j.bbrc.2020.05.050
163. Chonpathompikunlert P, Yingthongchai P, Tateing S, Amatachaya A, Kaewbutra S, Chaiyawan N, et al. Administration of a probiotic supplement attenuates nonalcoholic fatty liver disease by reducing hepatic lipid accumulation, oxidative stress, and inflammation. Biosci Microbiota Food Health. (2025) 44:160–70. doi: 10.12938/bmfh.2024-074
164. Fan C, Ling-Hu A, Sun D, Gao W, Zhang C, Duan X, et al. Nobiletin ameliorates hepatic lipid deposition, oxidative stress, and inflammation by mechanisms that involve the nrf2/NF-κB axis in nonalcoholic fatty liver disease. J Agric Food Chem. (2023) 71:20105–17. doi: 10.1021/acs.jafc.3c06498
165. Reis-Barbosa PH, Marinho TS, Matsuura C, Aguila MB, de Carvalho JJ, and Mandarim-de-Lacerda CA. The obesity and nonalcoholic fatty liver disease mouse model revisited: Liver oxidative stress, hepatocyte apoptosis, and proliferation. Acta Histochem. (2022) 124:151937. doi: 10.1016/j.acthis.2022.151937
166. Delli Bovi AP, Marciano F, Mandato C, Siano MA, Savoia M, and Vajro P. Oxidative stress in non-alcoholic fatty liver disease. An updated mini review. Front Med (Lausanne). (2021) 8:595371. doi: 10.3389/fmed.2021.595371
167. Allameh A, Niayesh-Mehr R, Aliarab A, Sebastiani G, and Pantopoulos K. Oxidative stress in liver pathophysiology and disease. Antioxidants (Basel). (2023) 12:1653–76. doi: 10.3390/antiox12091653
168. Chen S, Zhang L, Chen Y, Zhang X, and Ma Y. Chronic inflammatory and immune microenvironment promote hepatocellular carcinoma evolution. J Inflammation Res. (2023) 16:5287–98. doi: 10.2147/JIR.S435316
169. Hirsova P, Bohm F, Dohnalkova E, Nozickova B, Heikenwalder M, Gores GJ, et al. Hepatocyte apoptosis is tumor promoting in murine nonalcoholic steatohepatitis. Cell Death Dis. (2020) 11:80. doi: 10.1038/s41419-020-2283-9
170. Ohkubo R, Mu WC, Wang CL, Song Z, Barthez M, Wang Y, et al. The hepatic integrated stress response suppresses the somatotroph axis to control liver damage in nonalcoholic fatty liver disease. Cell Rep. (2022) 41:111803. doi: 10.1016/j.celrep.2022.111803
171. Drabovich AP, Martínez-Morillo E, and Diamandis EP. Toward an integrated pipeline for protein biomarker development. Biochim Biophys Acta. (2015) 1854:677–86. doi: 10.1016/j.bbapap.2014.09.006
172. Song B, Sun Y, Chu Y, Wang J, Zheng H, Liu L, et al. Ginsenoside rb1 alleviated high-fat-diet-induced hepatocytic apoptosis via peroxisome proliferator-activated receptor γ. BioMed Res Int. (2020) 2020:2315230. doi: 10.1155/2020/2315230
173. Liu E, Wang X, Li X, Tian P, Xu H, Li Z, et al. Co-exposure to multi-walled carbon nanotube and lead ions aggravates hepatotoxicity of nonalcoholic fatty liver via inhibiting AMPK/PPARγ pathway. Aging (Albany NY). (2020) 12:14189–204. doi: 10.18632/aging.103430
174. Dong X, Lu S, Tian Y, Ma H, Wang Y, Zhang X, et al. Bavachinin protects the liver in NAFLD by promoting regeneration via targeting PCNA. J Adv Res. (2024) 55:131–44. doi: 10.1016/j.jare.2023.02.007
175. Nascè A, Gariani K, Jornayvaz FR, and Szanto I. NADPH oxidases connecting fatty liver disease, insulin resistance and type 2 diabetes: current knowledge and therapeutic outlook. Antioxidants (Basel). (2022) 11:1131–67. doi: 10.3390/antiox11061131
176. Li S-W, Takahara T, Que W, Fujino M, Guo W-Z, Hirano S-I, et al. Hydrogen-rich water protects against liver injury in nonalcoholic steatohepatitis through HO-1 enhancement via IL-10 and Sirt 1 signaling. Am J Physiol Gastrointest Liver Physiol. (2021) 320:G450–63. doi: 10.1152/ajpgi.00158.2020
177. Wong AM, Ding X, Wong AM, Xu M, Zhang L, Leung HH-W, et al. Unique molecular characteristics of NAFLD-associated liver cancer accentuate β-catenin/TNFRSF19-mediated immune evasion. J Hepatol. (2022) 77:410–23. doi: 10.1016/j.jhep.2022.03.015
178. Fujiwara N and Nakagawa H. Clinico-histological and molecular features of hepatocellular carcinoma from nonalcoholic fatty liver disease. Cancer Sci. (2023) 114:3825–33. doi: 10.1111/cas.15925
179. Qin J, Zhu W, and Zhou W. Navigating the paradox of IL-22: friend or foe in hepatic health? J Gastroenterol Hepatol. (2025) 40:1393–408. doi: 10.1111/jgh.16991
180. Llovet JM, Willoughby CE, Singal AG, Greten TF, Heikenwälder M, El-Serag HB, et al. Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment. Nat Rev Gastroenterol Hepatol. (2023) 20:487–503. doi: 10.1038/s41575-023-00754-7
181. Wang X, Zhang L, and Dong B. Molecular mechanisms in MASLD/MASH-related HCC. Hepatology. (2025) 82:1303–24. doi: 10.1097/HEP.0000000000000786
182. Itoh M, Suganami T, and Ogawa Y. Role of chronic inflammation in the pathogenesis of nonalcoholic steatohepatitis: lessons from a unique mouse model using melanocortin receptor-deficient mice. Endocr J. (2021) 68:743–9. doi: 10.1507/endocrj.EJ21-0002
183. Zhang C-Y, Liu S, and Yang M. Regulatory T cells and their associated factors in hepatocellular carcinoma development and therapy. World J Gastroenterol. (2022) 28:3346–58. doi: 10.3748/wjg.v28.i27.3346
184. Tang W, Zhou J, Yang W, Feng Y, Wu H, Mok MTS, et al. Aberrant cholesterol metabolic signaling impairs antitumor immunosurveillance through natural killer T cell dysfunction in obese liver. Cell Mol Immunol. (2022) 19:834–47. doi: 10.1038/s41423-022-00872-3
185. Liang Y, Zhang R, Biswas S, Bu Q, Xu Z, Qiao L, et al. Integrated single-cell transcriptomics reveals the hypoxia-induced inflammation-cancer transformation in NASH-derived hepatocellular carcinoma. Cell Prolif. (2024) 57:e13576. doi: 10.1111/cpr.13576
186. Che Z, Xue W, Zhao X, Hu C, and Tian Y. Regulatory role and biomarker potential of gut microbiota metabolites in the progression of metabolic dysfunction-associated steatotic liver disease to hepatocellular carcinoma. Clin Transl Gastroenterol. (2025) 16:12–27. doi: 10.14309/ctg.0000000000000914
187. Monti E, Vianello C, Leoni I, Galvani G, Lippolis A, D’Amico F, et al. Gut microbiome modulation in hepatocellular carcinoma: preventive role in NAFLD/NASH progression and potential applications in immunotherapy-based strategies. Cells. (2025) 14:84–114. doi: 10.3390/cells14020084
188. Chaulagain RP, Padder AM, Shrestha H, Gupta R, Bhandari R, Shrestha Y, et al. Deciphering the matrisome: extracellular matrix remodeling in liver cirrhosis and hepatocellular carcinoma. Cureus. (2025) 17:e82171. doi: 10.7759/cureus.82171
189. Costante F, Airola C, Santopaolo F, Gasbarrini A, Pompili M, and Ponziani FR. Immunotherapy for nonalcoholic fatty liver disease-related hepatocellular carcinoma: Lights and shadows. World J Gastrointest Oncol. (2022) 14:1622–36. doi: 10.4251/wjgo.v14.i9.1622
190. Ruf B, Heinrich B, and Greten TF. Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells. Cell Mol Immunol. (2021) 18:112–27. doi: 10.1038/s41423-020-00572-w
191. Lombardi R, Piciotti R, Dongiovanni P, Meroni M, Fargion S, and Fracanzani AL. PD-1/PD-L1 immuno-mediated therapy in NAFLD: advantages and obstacles in the treatment of advanced disease. Int J Mol Sci. (2022) 23:2707–21. doi: 10.3390/ijms23052707
192. Da Fonseca LG, Freire CS, Guedes RAV, Lyra MC, Braguiroli MIFM, Siqueira MB, et al. Effectiveness and safety of immunotherapy for hepatocellular carcinoma in clinical practice: A Brazilian multicenter study. JCO Glob Oncol. (2025) 11:e2500128. doi: 10.1200/GO-25-00128
193. Said I, Ahad H, and Said A. Gut microbiome in non-alcoholic fatty liver disease associated hepatocellular carcinoma: Current knowledge and potential for therapeutics. World J Gastrointest Oncol. (2022) 14:947–58. doi: 10.4251/wjgo.v14.i5.947
194. Ohtani N, Kamiya T, and Kawada N. Recent updates on the role of the gut-liver axis in the pathogenesis of NAFLD/NASH, HCC, and beyond. Hepatol Commun. (2023) 7:e0241–52. doi: 10.1097/HC9.0000000000000241
195. Liu C, Ren L, Li X, Fan N, Chen J, Zhang D, et al. Self-electrochemiluminescence biosensor based on CRISPR/Cas12a and PdCuBP@luminol nanoemitter for highly sensitive detection of cytochrome c oxidase subunit III gene of acute kidney injury. Biosens Bioelectron. (2022) 207:114207. doi: 10.1016/j.bios.2022.114207
196. Li S-F, Ouyang X, Feng S, Wan M-Z, Zhou K-N, Wen B-Y, et al. Oncohepatology: Navigating liver injury in the era of modern cancer therapy. World J Hepatol. (2025) 17:106932. doi: 10.4254/wjh.v17.i6.106932
197. Gao B, Wang Y, Li C, and Lu S. Estrogen-related genes influence immune cell infiltration and immunotherapy response in Hepatocellular Carcinoma. Front Immunol. (2023) 14:1114717. doi: 10.3389/fimmu.2023.1114717
198. Cheng H, Zhou J, Sun Y, Zhan Q, and Zhang D. High fructose diet: A risk factor for immune system dysregulation. Hum Immunol. (2022) 83:538–46. doi: 10.1016/j.humimm.2022.03.007
199. Ayoub WS, Jones PD, Yang JD, and Martin P. Emerging drugs for the treatment of hepatocellular carcinoma. Expert Opin Emerg Drugs. (2022) 27:141–9. doi: 10.1080/14728214.2022.2083107
200. Nguyen-Khac E, Nahon P, Ganry O, Ben Khadhra H, Merle P, Amaddeo G, et al. Unresectable hepatocellular carcinoma at dawn of immunotherapy era: real-world data from the French prospective CHIEF cohort. Eur J Gastroenterol Hepatol. (2023) 35:1168–77. doi: 10.1097/MEG.0000000000002546
201. Ramadori P, Kam S, and Heikenwalder M. T cells: Friends and foes in NASH pathogenesis and hepatocarcinogenesis. Hepatology. (2022) 75:1038–49. doi: 10.1002/hep.32336
202. Sim BC, Kang YE, You SK, Lee SE, Nga HT, Lee HY, et al. Hepatic T-cell senescence and exhaustion are implicated in the progression of fatty liver disease in patients with type 2 diabetes and mouse model with nonalcoholic steatohepatitis. Cell Death Dis. (2023) 14:618. doi: 10.1038/s41419-023-06146-8
203. Zhong X, Lv M, Ma M, Huang Q, Hu R, Li J, et al. State of CD8(+) T cells in progression from nonalcoholic steatohepatitis to hepatocellular carcinoma: From pathogenesis to immunotherapy. BioMed Pharmacother. (2023) 165:115131. doi: 10.1016/j.biopha.2023.115131
204. Yin Y, Feng W, Chen J, Chen X, Wang G, Wang S, et al. Immunosuppressive tumor microenvironment in the progression, metastasis, and therapy of hepatocellular carcinoma: from bench to bedside. Exp Hematol Oncol. (2024) 13:72. doi: 10.1186/s40164-024-00539-x
205. Yu DD, Van Citters G, Li H, Stoltz BM, and Forman BM. Discovery of novel modulators for the PPARα (peroxisome proliferator activated receptor α): Potential therapies for nonalcoholic fatty liver disease. Bioorg Med Chem. (2021) 41:116193. doi: 10.1016/j.bmc.2021.116193
206. Liao J, Xie X, Wang N, Wang Y, Zhao J, Chen F, et al. Formononetin promotes fatty acid β-oxidation to treat non-alcoholic steatohepatitis through SIRT1/PGC-1α/PPARα pathway. Phytomedicine. (2024) 124:155285. doi: 10.1016/j.phymed.2023.155285
207. Wang K, Zhang Y, Wang G, Hao H, and Wang H. FXR agonists for MASH therapy: Lessons and perspectives from obeticholic acid. Med Res Rev. (2024) 44:568–86. doi: 10.1002/med.21991
208. Mungamuri SK and Vijayasarathy K. Role of the gut microbiome in nonalcoholic fatty liver disease progression. Crit Rev Oncog. (2020) 25:57–70. doi: 10.1615/CritRevOncog.2020035667
209. Zou B, Yang W, Tang Y, Hou Y, Tang T, and Qu S. Intestinal microbiota-farnesoid X receptor axis in metabolic diseases. Clin Chim Acta. (2020) 509:167–71. doi: 10.1016/j.cca.2020.06.006
210. Tian H, Zhang S, Liu Y, Wu Y, and Zhang D. Fibroblast growth factors for nonalcoholic fatty liver disease: opportunities and challenges. Int J Mol Sci. (2023) 24:4583–99. doi: 10.3390/ijms24054583
211. Kimura T, Pydi SP, Pham J, and Tanaka N. Metabolic functions of G protein-coupled receptors in hepatocytes-potential applications for diabetes and NAFLD. Biomolecules. (2020) 10:1445–61. doi: 10.3390/biom10101445
212. Xu C, Fu F, She Y, and Xu C. NPC1L1 plays a novel role in nonalcoholic fatty liver disease. ACS Omega. (2023) 8:48586–9. doi: 10.1021/acsomega.3c07337
213. Oh E, Lee J, Cho S, Kim SW, Won K, Shin WS, et al. Gossypetin prevents the progression of nonalcoholic steatohepatitis by regulating oxidative stress and AMP-activated protein kinase. Mol Pharmacol. (2023) 104:214–29. doi: 10.1124/molpharm.123.000675
214. Zhang Q, Wang J, Hu X, Lu W, Cao Y, Niu C, et al. GLP-1RAs regulate lipid metabolism and induce autophagy through AMPK/SIRT1 pathway to improve NAFLD. Prostaglandins Other Lipid Mediat. (2025) 178:106987. doi: 10.1016/j.prostaglandins.2025.106987
215. Kim M, Hwang I, Pagire HS, Pagire SH, Choi W, Choi WG, et al. Design, synthesis, and biological evaluation of new peripheral 5HT(2A) antagonists for nonalcoholic fatty liver disease. J Med Chem. (2020) 63:4171–82. doi: 10.1021/acs.jmedchem.0c00002
216. Rashed ZE, Grasselli E, Khalifeh H, Canesi L, and Demori I. Brown-algae polysaccharides as active constituents against nonalcoholic fatty liver disease. Planta Med. (2022) 88:9–19. doi: 10.1055/a-1273-3159
217. Hu Y-L, Ma Q, Dong X, Kong Y, Cai J, Li J, et al. Research progress on the therapeutic effects of polysaccharides on non-alcoholic fatty liver diseases. Front Nutr. (2023) 10:1107551. doi: 10.3389/fnut.2023.1107551
218. Wei X, Luo D, Li H, Li Y, Cen S, Huang M, et al. The roles and potential mechanisms of plant polysaccharides in liver diseases: a review. Front Pharmacol. (2024) 15:1400958. doi: 10.3389/fphar.2024.1400958
219. Yang F, Wu Y, Chen Y, Xi J, Chu Y, Jin J, et al. Human umbilical cord mesenchymal stem cell-derived exosomes ameliorate liver steatosis by promoting fatty acid oxidation and reducing fatty acid synthesis. JHEP Rep. (2023) 5:100746. doi: 10.1016/j.jhepr.2023.100746
220. Wang Y, Yu H, Cen Z, Zhu Y, and Wu W. Drug targets regulate systemic metabolism and provide new horizons to treat nonalcoholic steatohepatitis. Metabol Open. (2024) 21:100267. doi: 10.1016/j.metop.2023.100267
221. Rivera-Aguirre J, López-Sánchez GN, Chávez-Tapia NC, Uribe M, and Nuño-Lámbarri N. Metabolic-associated fatty liver disease regulation through nutri epigenetic methylation. Mini Rev Med Chem. (2023) 23:1680–90. doi: 10.2174/1389557523666230130093512
222. Qian G and Morral N. Role of non-coding RNAs on liver metabolism and NAFLD pathogenesis. Hum Mol Genet. (2022) 31:R4–R21. doi: 10.1093/hmg/ddac088
223. Schultz Moreira AR, Rüschenbaum S, Schefczyk S, Hendgen-Cotta U, Rassaf T, Broering R, et al. 9-PAHSA prevents mitochondrial dysfunction and increases the viability of steatotic hepatocytes. Int J Mol Sci. (2020) 21:8279–89. doi: 10.3390/ijms21218279
224. Newberry C and Kumar S. Dietary and nutrition considerations in caring for patients with nonalcoholic fatty liver disease: Updates for the practicing clinician. Nutr Clin Pract. (2023) 38:70–9. doi: 10.1002/ncp.10917
225. Younossi ZM, Corey KE, and Lim JK. AGA clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: expert review. Gastroenterology. (2021) 160:912–8. doi: 10.1053/j.gastro.2020.11.051
226. Vachliotis I, Goulas A, Papaioannidou P, and Polyzos SA. Nonalcoholic fatty liver disease: lifestyle and quality of life. Hormones (Athens). (2022) 21:41–9. doi: 10.1007/s42000-021-00339-6
227. Majumdar A, Verbeek J, and Tsochatzis EA. Non-alcoholic fatty liver disease: Current therapeutic options. Curr Opin Pharmacol. (2021) 61:98–105. doi: 10.1016/j.coph.2021.09.007
228. Shi Y and Qi W. Histone modifications in NAFLD: mechanisms and potential therapy. Int J Mol Sci. (2023) 24:14653–72. doi: 10.3390/ijms241914653
229. Koo BK, Lee H, Kwak S-H, Lee DH, Park JH, and Kim W. Long-term effect of PNPLA3 on the aggravation of nonalcoholic fatty liver disease in a biopsy-proven cohort. Clin Gastroenterol Hepatol. (2023) 21:1105–1107.e1103. doi: 10.1016/j.cgh.2022.02.026
230. Spiezia C, Di Rosa C, Fintini D, Ferrara P, De Gara L, and Khazrai YM. Nutritional approaches in children with overweight or obesity and hepatic steatosis. Nutrients. (2023) 15:2435–58. doi: 10.3390/nu15112435
231. Ciocca M and Álvarez F. Obesity-fatty liver: the role of the pediatrician. Arch Argent Pediatr. (2021) 119:427–30. doi: 10.5546/aap.2021.427
232. Gala K, Razzak FA, Rapaka B, and Abu Dayyeh BK. Novel endoscopic bariatric therapies for the management of nonalcoholic steatohepatitis. Semin Liver Dis. (2022) 42:446–54. doi: 10.1055/a-1946-6285
233. Yeoh A, Wong R, and Singal AK. The role bariatric surgery and endobariatric therapies in nonalcoholic steatohepatitis. Clin Liver Dis. (2023) 27:413–27. doi: 10.1016/j.cld.2023.01.009
234. Brown E, Hydes T, Hamid A, and Cuthbertson DJ. Emerging and established therapeutic approaches for nonalcoholic fatty liver disease. Clin Ther. (2021) 43:1476–504. doi: 10.1016/j.clinthera.2021.07.013
235. Satiya J, Snyder HS, Singh SP, and Satapathy SK. Narrative review of current and emerging pharmacological therapies for nonalcoholic steatohepatitis. Transl Gastroenterol Hepatol. (2021) 6:60. doi: 10.21037/tgh-20-247
236. Chen J, Chan TTH, and Zhou J. Lipid metabolism in the immune niche of tumor-prone liver microenvironment. J Leukoc Biol. (2024) 115:68–84. doi: 10.1093/jleuko/qiad081
237. Brown ZJ, Gregory S, Hewitt DB, Iacono S, Choe J, Labiner HE, et al. Safety, efficacy, and tolerability of immune checkpoint inhibitors in the treatment of hepatocellular carcinoma. Surg Oncol. (2022) 42:101748. doi: 10.1016/j.suronc.2022.101748
238. Lu Y, Li T, Song L, Fan Q, Wang D, Wang P, et al. MDSCs in chronic liver disease: updates and future challenges. J Gastroenterol Hepatol. (2025) 40:1659–66. doi: 10.1111/jgh.17008
239. Gomez-Torres O, Amatya S, Kamberov L, Dhaibar HA, Khanna P, Rom O, et al. SLAMF1 is expressed and secreted by hepatocytes and the liver in nonalcoholic fatty liver disease. Am J Physiol Gastrointest Liver Physiol. (2022) 323:G177–87. doi: 10.1152/ajpgi.00289.2021
240. Ma C, Wang S, Dong B, and Tian Y. Metabolic reprogramming of immune cells in MASH. Hepatology. (2025). doi: 10.1097/HEP.0000000000001371
241. Papadakos SP, Arvanitakis K, Stergiou IE, Vallilas C, Sougioultzis S, Germanidis G, et al. Interplay of extracellular vesicles and TLR4 signaling in hepatocellular carcinoma pathophysiology and therapeutics. Pharmaceutics. (2023) 15:2460–86. doi: 10.3390/pharmaceutics15102460
242. Qi X, Yang M, Stenberg J, Dey R, Fogwe L, Alam MS, et al. Gut microbiota mediated molecular events and therapy in liver diseases. World J Gastroenterol. (2020) 26:7603–18. doi: 10.3748/wjg.v26.i48.7603
243. Liu R, Qian M-P, and Cui Y-Y. Protein kinases: The key contributors in pathogenesis and treatment of nonalcoholic fatty liver disease-derived hepatocellular carcinoma. Metabolism. (2023) 147:155665. doi: 10.1016/j.metabol.2023.155665
244. Li Q, Wang M, Huang X, Wang S, Li C, Li P, et al. 6-Gingerol, an active compound of ginger, attenuates NASH-HCC progression by reprogramming tumor-associated macrophage via the NOX2/Src/MAPK signaling pathway. BMC Complement Med Ther. (2025) 25:154. doi: 10.1186/s12906-025-04890-2
245. Pan Y, Chen H, Zhang X, Liu W, Ding Y, Huang D, et al. METTL3 drives NAFLD-related hepatocellular carcinoma and is a therapeutic target for boosting immunotherapy. Cell Rep Med. (2023) 4:101144. doi: 10.1016/j.xcrm.2023.101144
246. Petagine L, Zariwala MG, and Patel VB. Non-alcoholic fatty liver disease: Immunological mechanisms and current treatments. World J Gastroenterol. (2023) 29:4831–50. doi: 10.3748/wjg.v29.i32.4831
247. Sawada K, Chung H, Softic S, Moreno-Fernandez ME, and Divanovic S. The bidirectional immune crosstalk in metabolic dysfunction-associated steatotic liver disease. Cell Metab. (2023) 35:1852–71. doi: 10.1016/j.cmet.2023.10.009
248. Jiang Z, Qian B, Xu T, Bai J, and Fu W. Immune microenvironment on the molecular mechanisms and therapeutic targets of MAFLD. Immunotargets Ther. (2025) 14:719–33. doi: 10.2147/ITT.S530451
249. Wang G, Li Z, Lin P, Zhang H, Wang Y, Zhang T, et al. Knockdown of Smox protects the integrity of the blood-brain barrier through antioxidant effect and Nrf2 pathway activation in stroke. Int Immunopharmacol. (2024) 126:111183. doi: 10.1016/j.intimp.2023.111183
250. Ostad-Ahmadi Z, Boccalini S, Daemi A, and Mahboub-Ahari A. Cost-effectiveness analysis of seasonal influenza vaccination during pregnancy: A systematic review. Travel Med Infect Dis. (2023) 55:102632. doi: 10.1016/j.tmaid.2023.102632
251. Yang M, Khoukaz L, Qi X, Kimchi ET, Staveley-O’Carroll KF, and Li G. Diet and gut microbiota interaction-derived metabolites and intrahepatic immune response in NAFLD development and treatment. Biomedicines. (2021) 9:1893–911. doi: 10.3390/biomedicines9121893
252. Shen S, Liu Y, Wang N, Huang Z, and Deng G. The role of microbiota in nonalcoholic fatty liver disease: mechanism of action and treatment strategy. Front Microbiol. (2025) 16:1621583. doi: 10.3389/fmicb.2025.1621583
253. Yin W, Gao W, Yang Y, Lin W, Chen W, Zhu X, et al. Disrupted host-microbiota crosstalk promotes nonalcoholic fatty liver disease progression by impaired mitophagy. Microbiol Spectr. (2025) 13:e0010025. doi: 10.1128/spectrum.00100-25
254. Huang Y, Xia X, Xu J, Wang Z, You Y, and Du Q. Mitophagy as a pivotal axis in non−alcoholic fatty liver disease: From pathogenic mechanisms to therapeutic strategies (Review). Mol Med Rep. (2025) 32:299–314. doi: 10.3892/mmr.2025.13664
255. Wei M, Tu W, and Huang G. Regulating bile acids signaling for NAFLD: molecular insights and novel therapeutic interventions. Front Microbiol. (2024) 15:1341938. doi: 10.3389/fmicb.2024.1341938
256. Radun R and Trauner M. Role of FXR in bile acid and metabolic homeostasis in NASH: pathogenetic concepts and therapeutic opportunities. Semin Liver Dis. (2021) 41:461–75. doi: 10.1055/s-0041-1731707
257. Zhao Q, Wu J, Ding Y, Pang Y, and Jiang C. Gut microbiota, immunity, and bile acid metabolism: decoding metabolic disease interactions. Life Metab. (2023) 2:load032. doi: 10.1093/lifemeta/load032
258. Xiao Z, Liu M, Yang F, Liu G, Liu J, Zhao W, et al. Programmed cell death and lipid metabolism of macrophages in NAFLD. Front Immunol. (2023) 14:1118449. doi: 10.3389/fimmu.2023.1118449
259. Cai F, Jin S, and Chen G. The effect of lipid metabolism on CD4(+) T cells. Mediators Inflammation. (2021) 2021:6634532. doi: 10.1155/2021/6634532
260. Deng C-J, Lo T-H, Chan K-Y, Li X, Wu M-Y, Xiang Z, et al. Role of B lymphocytes in the pathogenesis of NAFLD: A 2022 update. Int J Mol Sci. (2022) 23:12376–88. doi: 10.3390/ijms232012376
261. Gong J, Gao X, Ge S, Li H, Wang R, and Zhao L. The role of cGAS-STING signalling in metabolic diseases: from signalling networks to targeted intervention. Int J Biol Sci. (2024) 20:152–74. doi: 10.7150/ijbs.84890
262. Bai J and Liu F. cGAS–STING signaling and function in metabolism and kidney diseases. J Mol Cell Biol. (2021) 13:728–38. doi: 10.1093/jmcb/mjab066
263. Jimenez-Duran G and Triantafilou M. Metabolic regulators of enigmatic inflammasomes in autoimmune diseases and crosstalk with innate immune receptors. Immunology. (2021) 163:348–62. doi: 10.1111/imm.13326
264. Wang Z, Chen W-D, and Wang Y-D. Nuclear receptors: a bridge linking the gut microbiome and the host. Mol Med. (2021) 27:144. doi: 10.1186/s10020-021-00407-y
265. Wen W, Wu P, Zhang Y, Chen Z, Sun J, and Chen H. Comprehensive analysis of NAFLD and the therapeutic target identified. Front Cell Dev Biol. (2021) 9:704704. doi: 10.3389/fcell.2021.704704
266. Kim JE, Kim E, and Lee JW. TM4SF5-mediated regulation of hepatocyte transporters during metabolic liver diseases. Int J Mol Sci. (2022) 23:8387–401. doi: 10.3390/ijms23158387
Keywords: cancer immunotherapy, hepatocellular carcinoma, immunometabolism, non-alcoholic steatohepatitis, regulators, tumor microenvironment
Citation: Liu L, Duan X and Ju B (2026) Recent advances in non-alcoholic steatohepatitis-associated hepatocellular carcinoma: immune cells, metabolic dysregulation, and therapeutic strategies. Front. Oncol. 15:1744299. doi: 10.3389/fonc.2025.1744299
Received: 11 November 2025; Accepted: 30 December 2025; Revised: 29 December 2025;
Published: 21 January 2026.
Edited by:
Di Du, ExxonMobil Research and Engineering, United StatesReviewed by:
Cena Aram, Kharazmi University, IranXiangyu Zhai, The Second Hospital of Shandong University, China
Copyright © 2026 Liu, Duan and Ju. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Baozhao Ju, anViYW96aGFvQDE2My5jb20=